Guías clínicas para el manejo del infarto agudo del miocardio con elevación del segmento ST

Grupo de Trabajo de la Sociedad Mexicana de Cardiología y Asociación Nacional de Cardiólogos de México

Miembros:

Armando García–Castillo, Carlos Jerjes Sánchez–Díaz, Carlos Martínez Sánchez, Guillermo Llamas Esperón, Ernesto Cardona, Rodolfo Barragán, Felipe González–Camid, Guillermo Sahagún, Alfonso J. Treviño

La lista completa de participantes se encuentra en el apéndice del documento

Correspondencia: ]]> Armando García–Castillo
Hidalgo 2525 Pte int 508, Col Obispado, Monterrey NL 64060
E–mail: armandogc1@prodigy.net.mx

Palabras clave: Infarto agudo del miocardio. Cardiopatía isquémica. Síndrome coronario agudo. Terapia farmacológica.

Key words: Acute myocardial infarction. Ischaemic heart disease. Acute coronary syndroms. Drug therapy.

Texto del artículo

Listado de participantes

Referencias

1. Secretaría de Salud (México) Causas de mortalidad en México 2001. Estadísticas de mortalidad. http://www.ssa.gob.mex        [ Links ]

2. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature: Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979; 59: 607–609.        [ Links ]

3. Porela P, Helenius H, Pulkki K, Voipio–Pulkkil L–M: Epidemiological classification of acute myocardial infarction: time for a change? Eur Heart J 1999; 20: 1459–1464.        [ Links ]

4. Antman EM, Bassand JP, Klein W, Ohman M, Lopez–Sendón JL, Ryden L, et al: A Consensus Document of The Joint European Society of Cardiology//American College of Cardiology Committee for Redefinition of Myocardial Infarction: Myocardial Infarction Redefined. J Am Coll Cardiol 2000; 36: 959–969.        [ Links ]

5. Fishbein MC, Mc Lean D, Maroko PR: The histopathological evolution of myocardial infarction. Chest 1978; 73: 743–749.        [ Links ]

6. Jennings RB, Reimer KA: Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood. Circulation 1983; 68 Suppl I: 1–25–36.        [ Links ]

7. Buja LM: Modulations of the myocardial response to injury. Lab Invest 1998; 78: 1345–1373.        [ Links ]

8. Antman EM, Sacks DB, Rifai N, Mc Cabe CH, Cannon CP, Braunwald E: Time to positivity of a rapid cardiac–specific troponin T predicts prognosis in acute coronary syndromes: a thrombolysis In Myocardial Infarction (TIMI) 11A substudy. J Am Coll Cardiol 1998; 31: 326–330.        [ Links ]

9. Antman EM: Troponin Measurements in Ischemic Heart Disease: More Than Just a Black and White Picture. J Am Coll Cardiol 2001; 38: 987–990.        [ Links ]

10. Apple FS: Clinical and analytical standardization issues confronting cardiac troponin I. Clin Chem 1999;45: 18–20.        [ Links ]

11. Apple FS: Tissue specificity of cardiac troponin I, cardiac troponin T, and creatine kinase MB. Clin Chem Acta 1999; 284: 151–158.        [ Links ]

12. Gerhardt W, Nordin G, Ljungdahl I: Can troponin T replace CK–MB mass "gold standard" for acute myocardial infarction ("AMI"')? Scan J Clin Lab Inves 1999; 59 Suppl 230: 83–89.        [ Links ]

12a. Zimetbaum PJ, Josephson ME: Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348: 933–940        [ Links ]

12b. Van de Werf FJ, Topol EJ: Acute phase treatment of myocardial infarction selecting patients for thrombolysis pag. 471–481. En: Cardiovascular thrombosis. Edit. Marc Verestrate, Valentin Fuster, Eric J. Topol. Lippincott– Raven 2nd edition 1992.        [ Links ]

13. Menown BA, Mackenzie G, Adgey A A: Optimizing the initial 12–lead electrocardiographic diagnosis of acute myocardial infarction. Eur Heart J 2000; 21: 275–283.        [ Links ]

14. Antman EM, Braunwald E: Acute myocardial infarction. En: Braunwald EB, Ed: Heart disease: a textbook of cardiovascular medicine. Philadelphia, PA: W Saunders 1997.        [ Links ]

15. Peels C, Visser CA, Funkekupper AJ, Visser FC, Ross JP: Usefulness of two–dimensional echocardiography for immediate detection of myocardial ischemia in the emergency room. Am J Cardiol 1990; 65: 687–691.        [ Links ]

16. Buda AJ: The role of echocardiography in the evaluation of mechanical complications of acute myocardial infarction. Circulation 1991; 84 Suppl I: 1–109–121.        [ Links ]

17. Armstrong A, Duncan B, Oliver MF, Julian DG, Donald KW, Fulton M, et al: Natural history of acute coronary attacks. A community study. Br Heart J 1972; 34: 67–80.        [ Links ]

18. Tunstall–Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruko–Koski E, Amouyel P, for the WHO MONICA Project: Contribution of trends of survival and coronary–event rates to changes in coronary heart disease mortality: 10–year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353: 1547–57.        [ Links ]

19. De Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, Wellens HJ: Did prognosis after acute myocardial infarction change during the past 30 years? A meta–analysis. J Am Coll Cardiology 1991; 18: 698–706.        [ Links ]

20. Hasai D, Begar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. (Euro Heart Survey ACS). Eur Heart J 2002; 15: 1190–1201.        [ Links ]

21. Grupo Cooperativo RENASICA. Sociedad Mexicana de Cardiología: El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos (RENASICA). Arch Cardiol Méx 2002; 72 Supl: S45–S64.        [ Links ]

22. Herrick JB: Clinical features of sudden obstruction of the coronary arteries. JAMA 1912; 59: 2015.        [ Links ]

23. De Wood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, et al: Prevalence of total coronary occlusion during of early hours of transmural myocardial infarction. N Engl J Med 1989; 303: 897–902.        [ Links ]

24. Dalager–Pederson S, Pederson EM, Ringgaard S, Falk E: Arteriopatía Coronaria: vulnerabilidad de la placa, rotura y trombosis. En: FUSTER V ed: La placa de ateroma vulnerable. Serie Monográfica de la American Heart Association. Barcelona, Medical Trends, SL, 1999.        [ Links ]

25. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, et al: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Circulation 1995; 92: 1355–1374.        [ Links ]

26. Davies MJ, Thomas AC: Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363–373.        [ Links ]

27. Richardson PD, Davies MJ, Born GVR: Influence of plaque configuration and stress distribution of fissuring on coronary atherosclerotic plaques. Lancet 1989; II: 941–944.        [ Links ]

28. Falk E: Coronary thrombosis: Pathogenesis and clinical manifestations. Am J Cardiol 1991; 68 (Suppl B): 28B–35B.        [ Links ]

29. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–2850.        [ Links ]

30. Frink RJ, Ostrach LH, Rooney PA, Rose: Coronary thrombosis, ulcerated atherosclerotic plaques and platelet/fibrin microemboli in patients dying with acute coronary disease: a large autopsy study. J Clin Invest 1990; 2: 199–210.        [ Links ]

31. Fuster V, Badimón JJ, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. (Part I and II) N Engl J Med 1992; 326: 242–250.        [ Links ]

32. Badimón JJ, Badimón L, Fuster V: Efecto de la reología en la trombosis. En: FUSTER V ed: La placa de ateroma vulnerable. Serie Monográfica de la American Heart Association. Barcelona, Medical Trends, SL, 1999.        [ Links ]

33. Lefkovits J, Plow EF, Topol EJ: Platelets glycoprotein IIb/IIIa receptors in cardio-vascular medicine. N Engl J Med 1995; 332: 1553–1559.        [ Links ]

34. Sobel BE: Coronary thrombolysis and the new biology. J Am Coll Cardiol 1989; 14: 850–859.        [ Links ]

35. Topol EJ, Yadav JS: Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101: 570–580.        [ Links ]

36. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology: Management of acute myocardial infarction presenting with ST–segment elevation. Eur Heart J 2003; 24: 28–66.        [ Links ]

37. Adams J, Trent R, Rawles J, on behalf of the GREAT Group: Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic therapy. BMJ 1993; 307:409–413.        [ Links ]

38. Grijseels EW, Deckers JW, Hoes AW, Hartam JA, Van der Does E, Van Loenen E, et al: Pre–hospital triage of patients with suspected acute myocardial infarction. Evaluation of previously developed algorithms and new proposals. Eur Heart J 1995; 16: 325–332.        [ Links ]

39. Hauser AM, Gangadharan V, Ramos RG, Gordon S, Timmis GC: Sequence of mechanical, electrocardio graphic and clinical effects of repeated coronary occlusion in human beings: echocardiographic observations during coronary angioplasty. J Am Coll Cardiol 1985; 5: 193–197.        [ Links ]

40. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, et al, for the GUSTO–I Investigators: Predictors of 30–day mortality in the era of reperfusion for acute myocardial infarction. Results of an international trial of 41,021 patients. Circulation 1995: 91: 1659–1668.        [ Links ]

41. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, De Lemos JA, et al: TIMI risk score for ST–segment elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intra–venous nPA for treatment of infarcting myocardium early II trial substudy .Circulation 2000; 102:2031–2037.        [ Links ]

42. Morrow DA, Antman EM, Giugliano RP, Cairns R, Charlesworth A, Murphy SA, et al: A simple risk index for rapid triage of patients with ST–elevation myocardial infarction: an In TIME II substudy. Lancet 2001; 358: 1571–1575.        [ Links ]

43. Tanaka A, Shimada K, Sano T, Namba M, Sakamoto T, Nishida Y, Kawarabayashi T, Fukuda D, Yoshikawa J. Multiple plaque rupture and C–reactive protein in acute myocardial infarction. J Am Coll Cardiol 2005; 45: 1594–1599.        [ Links ]

44. Bertrand ME, Simoons ML, Fox KAA, Walentin LC, Hamm CW, McFadden E, De Feyter PJ: Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–1432.        [ Links ]

45. García–Castillo A, Jerjes–Sanchez C, Martinez BP, Azpiri–Lopez JR, Autrey C A, Martinez SC, Ramos CMA, Llamas G, Martinez SJ: RENASICA II. A Mexican registry of acute coronary syndromes. Arch Cardiol Mex 2005; 75: S18–S30.        [ Links ]

46. Libby P, Theroux P. Pathophysiology of Coronary Artery Disease. Circulation 2005; 111: 3481–3488.        [ Links ]

46a. Panteghini M: Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25:1187–1196.        [ Links ]

47. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, López–Sendón, for the GRACE Investigators: Practice variation and missed opportunities for reperfusion in ST–segment–elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359: 373–377.        [ Links ]

48. Report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures, Committee on Radionuclide Imaging in collaboration with the American Society of Nuclear Cardiology: Guidelines for clinical use of cardiac radionuclide imaging. J Am Coll Cardiol 1995; 25: 521–547.        [ Links ]

49. Reeder S: Advanced Cardiac MR imaging of ischemic heart disease. Radiographics 2000; 21: 1047–1074.        [ Links ]

50. Klein C, Nekolla S, Bengel E, Momose M, Sammer A, Haas F, et al: Assessment of Myocardial Viability With Contrast–Enhanced Magnetic Resonance Imaging: Comparison With Positronic Emission Tomography. Circulation 2000; 105: 162–167.        [ Links ]

50a. Maroko PR, Radvany P, Braunwald E, Hale SL: Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 1975; 52: 360–368.        [ Links ]

50b. Madias JE, Hoode WB: Reduction of precordial ST–segment elevation in patients with anterior myocardial infarction by oxygen breathing. Circulation 1976; 53: 198–200.        [ Links ]

50c. Fillmore SJ, Shapiro M, Killip T: Arterial oxygen tension in acute myocardial infarction: serial analysis of clinical state and blood gas changes. Am Heart J 1970; 79: 620–629.        [ Links ]

51. Vatner SF, Me Ritchie RJ, Maroko PR, Patrick TA, Braunwald E: Effects of cathecolamines, exercise and nitroglycerin, on the normal and ischemic myocardian in conscious dogs. J Clin Invest. 1974; 54: 563–575.        [ Links ]

51a. Antman EM, Braunwald E. Acute myocardial infarction. En: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia, PA: WB Saunders Co Ltd; 2001: 1114–1251.        [ Links ]

52. Madias JE, Hood WB Jr: Reduction of infarct size by oxygen inhalation following myocardial infarction by oxygen breathing. Circulation, 1976; 79: 620–629.        [ Links ]

52a. ACC/AHA Guidelines for the Management of Patients ST–Elevation Myocardial Infarction. A Report of the American College of Cardiology/ American Heart Association. Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management Patients With Acute Myocardial Infarction) ACC – www.acc.org/AHA –www.americanheart.org        [ Links ]

53. ACC/AHA. Guidelines for the management of patients with myocardial infarction. 1999.        [ Links ]

53a. ISIS–4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS–4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85.        [ Links ]

54. Yusuf S, Collins R, MacMahon S, Peto R: Effect of intravenuos nitrates on mortatily in acute myocardial infarction: an overview of the randomized trials. Lancet 1988; 1: 1088–1092.        [ Links ]

54a. Al Bazzaz FJ, Kazemi H: Arterial hypoxemia and distribution of pulmonary perfusión after uncomplicated myocardial infarction. Am Rev Respir Dis 1972; 106: 721–728.        [ Links ]

55. Fourth International Study of infarct Survival (ISSIS–4) Collaborative Group: A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients suspected acute myocardial infarction. Lancet 1995; 345: 669–685.        [ Links ]

55a. Kazemi H, Parsons EF, Valencia LM, et al. Distribution of pulmonary blood flow after myocardial ischemia and infarction. Circulation 1970; 41: 1025–1030.        [ Links ]

56. Grupo Italiano per lo studio della streptochinasi nell infarto miocardio (GISSI) GISSI3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after myocardial infarction. Lancet 1994; 343: 1115–1122.        [ Links ]

56a. Greene R, Hoop B, Kazemi H: Use of 13N in studies of airway closure and regional ventilation. J Nucl Med 1971; 12: 719–723.        [ Links ]

57. Dixon RA, Edwards IR, Pilcher J: Diazepam in immediate post–myocardial infarct period: a double blind trial. Br Heart J 1980; 45: 535–540.        [ Links ]

57a. Hales CA, Kazemi H: Small airways function in myocardial infarction. N Engl J Med 1974; 290: 761–765.        [ Links ]

58. Antiplatelet Trialist Collaboration: Collaborative overview of randomized trial of antiplatelet therapy: prevention of death, myocardial infarction and strokeby prolonged antiplatelet therapy in various categories of people. BMJ 1994; 308:81–106.        [ Links ]

58a. Higgs BE: Factors influencing pulmonary gas exchange during the acute stages of myocardial infarction. Clin Sci 1968; 35: 115–122.        [ Links ]

59. Second International Study of infarct Survival (ISSIS 2) Collaborative Group: Randomized trials of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; II: 349–360.        [ Links ]

60. Sleight P, for the ISSIS study Group: Beta blockade early in acute myocardial infarction. Am J Cardiol 1987; 60: 6A–12A.        [ Links ]

61. First International Study of Infarct Survival (ISSIS 1): Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986: ii57–56.        [ Links ]

62. CAPRICORN Investigators: The effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385–90.        [ Links ]

63. ACE inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202–2212.        [ Links ]

64. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low molecular weight heparin with unfractioned heparin for unstable coronary artery disease. N Englan J Med 1997; 337; 447–52.        [ Links ]

65. ISSIS 3: A randomized comparison of streptokinase vs tPA vs anistrplase and asprin plus heparin vs aspirin alone among 41,299 cases of suspected myocardial infarction. Lancet 1992; 339: 753–70.        [ Links ]

66. Cohen M, Theroux P, Frey MJ, et al: Anthithrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation 2002; 102:11–826.        [ Links ]

67. Gusto IV–ACS investigators: The Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization. The Gusto IV trial. Lancet 2001; 357: 1915–24.        [ Links ]

68. Schawrtz GG, Oisson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized trial. JAMA 2001; 285: 1711–1718.        [ Links ]

69. Bybee KA, Wright RS, Williams BA, Braunwald E: Early statin therapy is associatedwith markedly lower mortality in patient with acute coronary syndromes. Observations for OPUSTIMI 16. J Am Coll Cardiol 2001; 37: A334.        [ Links ]

70. Diaz R, Paolasso EA, Piegas LS, et al: Metabolic Modulation of acute myocardial infarction: The ECLA (Estudios Cardiológicos Latinoamericanos) Collaborative Group. Circulation 1998; 98: 2227–2234.        [ Links ]

70b. Metha S: CREATE–ECLA–GIK Trial. Presented at AHA, 2004.        [ Links ]

71. Jerjes–Sánchez C, Del Ángel SE, García SA, Reyes CE, Garza RA: Estrategias para mejorar la reperfusión con terapia fibrinolítica en infarto con elevación del ST. Arch Cardiol Mex 2003; 73: 46–58.        [ Links ]

72. Bertrand ME, McFadden EP: Late is perhaps not....to late for primary PCI in acute myocardial infarction. Eur Heart J 2002; 23: 1146–1148.        [ Links ]

73. Gibson M: A union in reperfusion: the concept of facilitated percutaneous coronary intervention. J Am Coll Cardiol 2000; 36: 1497–1499.        [ Links ]

74. The Cardiac Catheterization and Antithrombotic Therapy and Tools in Hospital (CATH) Clinical Consensus: Acute coronary Syndromes. Interventional Cardiology Consensus Report. Editor Gideon Bosker, 2003: 233–268.        [ Links ]

75. Nallamothu BK, Bates ER: Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92: 824–26.        [ Links ]

76. Van de Werf F, Califf RM, Armstrong PW: On behalf of the GUSTO–I Steering Committee Progress culminating from ten years of clinical trials of thrombolysis for acute myocardial infarction. Eur Heart J 1995; 16: 1024–1026.        [ Links ]

77. DeWood MA, Spores J, Notske R, Lowell T, Mouser T, Burroughs R, et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 330: 897–902.        [ Links ]

78. Braunwald E: Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expended? Circulation 1989; 79: 441–444.        [ Links ]

79. Cannon CP, Antman EM, Walls R, Braunwald E: Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994; 1: 27–34.        [ Links ]

80. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402.        [ Links ]

81. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI): Long term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987; 2: 871–874.        [ Links ]

82. ISAM Study Group: A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity and infarct size at 21 days. N Engl J Med 1986; 314: 1465–1469.        [ Links ]

83. Shroeder R, Neuhaus KL, Linderer T, Leizorovicz A, Wegscheider K, Tebbe U, for the ISAM Study Group: Risk of death from recurrent ischemic events after intravenous streptokinase in acute myocardial infarction: results from the Intravenous Streptokinase in Myocardial Infarction (ISAM) Study. Circulation 1987; 76(Suppl 2): 1144–1151.        [ Links ]

84. Shroeder R, Neuhaus KL, Leizorovicz A, Linderer T, Tebbe U, for the ISAM Study Group: A prospective placebo–controlled double–blind multicenter trial of intravenous streptokinase (ISAM); long–term mortality and morbidity in acute myocardial infarction. J Am Coll Cardiol 1987; 9: 197–203.        [ Links ]

85. Wilcox RG, Olsson CG, Skene AM, et al, for the ASSET Study Group Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525–530.        [ Links ]

86. AIMS Trial Study Group: Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo–controlled clinical trial. Lancet 1988; 1: 545–549.        [ Links ]

87. Kennedy JW, Martin GV, Davis KB: The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 1988; 77: 345–352.        [ Links ]

88. Chaitman BR, Thompson B, Wittry MD: The use of tissue type plasminogen activator for acute myocardial infarction in the elderly: results from Thrombolysis in Myocardial Infarction Phase I open label studies and the Thrombolysis in Myocardial Infarction Phase II Pilot Study. J Am Coll Cardiol 1989; 14: 1159–65.        [ Links ]

89. The TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. N Engl J Med 1989; 320: 618–627.        [ Links ]

90. Tebbe U, Tanswell P, Seifried E, Feuerer W, Scholtz KH, Hermann KS: Single bolus injection of recombinant tissue–type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448–453.        [ Links ]

91. Neuhaus K, Feuerer W, Jeep–Tebbe, Niederer W, Vogt A, Tebbe U: Improved thrombolysis with a modified dose regimen of recombinant tissue–type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566–1569.        [ Links ]

92. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI–2): A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71.        [ Links ]

93. The International Study Group: In–hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 673–682.        [ Links ]

94. The GUSTO investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.        [ Links ]

95. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group: Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767–772.        [ Links ]

96. LATE Study Group: Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hs after onset of acute myocardial infarction. Lancet 1993; 342: 759–766.        [ Links ]

97. Fibrinolytic Therapy Trialist's (FTT) Collaborative Groups: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of mortality and major mortality results from randomized trials of more than 1,000 patients. Lancet 1994; 343: 311–322.        [ Links ]

98. Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, et al: Loaded recombinant tissue–type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24: 1602–1610.        [ Links ]

99. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–1123.        [ Links ]

100. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, et al: TNK–tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 10A dose ranging trial. Circulation 1997; 95: 351–356.        [ Links ]

101. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT–2) Investigators: Single–bolus tecneplase compared with front–loaded alteplasa in acute myocardial infarction: the ASSENT–2 double–blind randomized trial. Lancet 1999; 354: 716–722.        [ Links ]

102. The in Time–II Investigators: Intravenous NPA for the treatment of infarcting myocardium early. Eur Heart J 2000; 21: 2005–2013.        [ Links ]

103. Assessment of the safey and efficacy of a new thrombolytic regimen (ASSENT–3) Investigators: Efficacy and safety of tecneplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001; 358: 605–613.        [ Links ]

104. The Hirulog and Early Reperfusion or Occlusion (HERO)–2 Trial investigators: Thrombin specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO–2 randomized trial. Lancet 2001; 358: 1855–1863.        [ Links ]

105. Simmons ML, Krzemiñska–Pakula M, Alonso A, Goodman SG, Kali A, Loss U, et al, for the AMI–SK investigators: Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. Eur Heart J 2002; 23: 1282–1290.        [ Links ]

106. Rawles J: What is the likely benefit of earlier thrombolysis? Eur Heart J 1999; 617: 991–995.        [ Links ]

107. Boersma E, Mass ACP, Deckers JW, Simoons ML: Early thrombolytic treatment in acute myocardial infarction; reappraisal of the golden hour. Lancet 1996; 348: 771–775.        [ Links ]

108. Yusuf S, Collins R, Peto R: Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556–585.        [ Links ]

109. Jerjes–Sánchez C, Garza–Ruíz A, Gutiérrez–Fajardo: Trombólisis farmacológica en el infarto agudo del miocardio: lecciones aprendidas después del ISIS–2 y GUSTO I. (Parte I) Arch Inst Cardiol Mex 1999; 69: 478–487.        [ Links ]

110. Topol EJ, Califf RM, Vandormael M, by the Thrombolysis in Acute Myocardial Infarction Group (TAMI–6): A randomized trial of late reperfusion therapy for acute myocardial infarction. Circulation 1992; 85: 2090–2099.        [ Links ]

111. Romero MA, Espinoza VA, Ramos CMA, Solorio S, Lepe ML, Badui E, et al: Limitación de la expansión miocárdica con trombólisis tardía evaluada por ecocardiografía bidimensional. Arch Inst Cardiol Mex 1996; 66: 484–488.        [ Links ]

112. The European Myocardial Infarction Project Group: Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 382–389.        [ Links ]

113. Weaver WD, Cerqueria M, Hallstrom AP, for the Myocardial Infarction Triage and Intervention Project Group: Prehospital–initiated vs hospital–initiated thrombolytic therapy. JAMA 1993; 270:1211–1216.        [ Links ]

114. GREAT Group: Feasibility safety and efficacy of domiciliary thrombolysis by general practitioners. Br Med J 1992; 305: 548–553        [ Links ]

115. Fath–Ordoubadi F, Al–Mohammad A, Heuns TY, Geatt KJ: Pre–hospital thrombolysis does it save extra lives compared to hospital thrombolysis? An overview of randomized trials (Abstract). Eur Heart J 1995; 16 (suppl)123.        [ Links ]

116. Rain MH, Maynard C, Wagner GS, Cerqueria MD, Selvester RH, Weaver WD: Relation between symptoms duration before thrombolytic therapy and final myocardial infarct size. Circulation 1996; 93: 45–53.        [ Links ]

117. Morrow DA, Antman EM, Sayah A, Schuhwerk KC, Giugliano RP, deLemos JA, et al, on the behalf Early Retavase–Thrombolysis in Myocardial infarction (ER–TIMI) 19 Trial: Evaluation of the time saved by prehospital initiation of reteplase for ST elevation myocardial infarction. J Am Coll Cardiol 2002; 40: 71–77.        [ Links ]

118. Pedley DK, Bissett K, Connolly EM, Goodman CG, Golding I, Pringle TH, et al: Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ 2003; 327: 22–26.        [ Links ]

119. Keeling P, Hughes D, Price L, Shaw S, Barton A: Safety and feasibility of prehospital thrombolysis carried out by paramedics. BMJ 2003; 327: 27–28.        [ Links ]

120. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PE, et al: Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002; 360: 825–829.        [ Links ]

121. Lange RA, Hillis LD: Immediate angioplasty for acute myocardial infarction. N Engl J Med 1993; 328: 726–728.        [ Links ]

122. Holmes DR, Bates ER, Kleiman NS: Contemporary reperfusion therapy for cardiogenic shock: the GUSTO–I trial experience. J Am Coll Cardiol 1995; 26: 668–674.        [ Links ]

123. de Belder MA: Acute myocardial infarction: thrombolysis. Heart 2001; 85: 104–112.        [ Links ]

124. Arriaga NR, Olivas BM, Jerjes–Sánchez C. Trombólisis de rescate con dosis repetidas de estreptoquinasa en el infarto agudo del miocardio. Reporte preliminar. Arch Inst Cardiol Mex 1995; 65: 323–329.        [ Links ]

125. White HD, Cross DB, Norris RM, Williams BF: Early infarct artery patency after intravenous streptokinase, intracoronary contrast and intracoronary rt–PA. J Am Coll Cardiol 1992; 1: 275A.        [ Links ]

126. Barbash GI, Hod H, Roth A, Faibel HE, Mandel Y, Miller HI, et al: Repeat infusions of recombinant tissue–type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. J Am Coll Cardiol 1990; 16: 779–783.        [ Links ]

127. White HD, Cross DB, Williams BF, Norris RM: Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction. Br Heart J 1990; 64: 177–181.        [ Links ]

128. Simmons ML, Arnout J, van den Brand M, Nassen K, Verstraete M: Retreatment with alteplase for early signs of reoclusion after thrombolysis. Am J Cardiol 1993; 71: 524–528.        [ Links ]

129. Kucia MA, Zeitz JC: Failed reperfusion after thrombolytic therapy: recognition and management. Heart Lung 2002; 31: 113–121.        [ Links ]

130. Reyes–Cerezo E, Jerjes–Sánchez C, García–Sosa A, Garza–Ruiz A, Villarreal S: Trombólisis de rescate o retrombólisis en SCA con elevación persistente del ST. Revisión sistematizada. Arch Cardiol Mex 2003; 73: S2–17.        [ Links ]

131. Goldman LE, Eisemberg MJ: Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med 2000; 132: 556–565.        [ Links ]

132. Jerjes–Sánchez C, Garza–Ruiz A, Gutiérrez–Fajardo P, Villarreal CG: Nuevas estrategias para la estratificación y tratamiento de los síndromes isquémicos coronarios agudos. Una propuesta. Arch Inst Cardiol Mex 1999; 69: 163–175.        [ Links ]

133. Jerjes–Sánchez C, Garza–Ruiz A, Gutiérrez–Fajardo: Trombólisis farmacológica en el infarto agudo del miocardio: lecciones aprendidas después del ISIS–2 y GUSTO I. (Parte II) Arch Inst Cardiol Mex 1999; 69: 570–579.        [ Links ]

134. GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibitions: the GUSTO V randomized trial. Lancet 2001; 357: 1905–1914.        [ Links ]

135. Lew AS, Hod H, Cercek B, Shah PK, Ganz W: Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. Am J Cardiol 1987; 59: 1–5.        [ Links ]

136. Ruiz–Gastelum E, Jerjes–Sánchez C: Prevalencia de complicaciones hemorrágicas e indicadores de riesgo para hemorragia intracraneana en pacientes con IAM sometidos a trombólisis farmacológica. Arch Inst Cardiol Mex 1993; 61: 85.        [ Links ]

137. O'Connor CM, Califf RM, Massey EW, Mark DB, Uglieta J, Mark DB, et al: Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long–term prognosis. J Am Coll Cardiol 1990; 16: 533–540.        [ Links ]

138. Kase CS, O'Neal AM, Fisher M, Girgis GN, Ordia JL: Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990; 112: 17–21.        [ Links ]

139. Narváez J, Martínez–Enríquez A, Jerjes–Sánchez C: Trombólisis en el infarto agudo del miocardio e hipertensión arterial grave. Arch Inst Cardiol Mex 1993; 61: 58.        [ Links ]

140. Cannon C: Overcoming Thrombolytic resistance. Rationale and initial clinical experience combining thrombolytic therapy and Glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1395–1402.        [ Links ]

141. Antman EM, Giugliano OR, Gibson M, Carolyn H, McCabe HC, Coussement P, et al: Abxicimab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation 1999; 99: 2720–32.        [ Links ]

142. Ohman EM, Kleiman NS, Gacioch G: Combined accelerated tissue–plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with untegrilin in acute myocardial infarction: results of a randomized, placebo–controlled, dose–ranging. Circulation 1997; 32: 381–9.        [ Links ]

143. Ronner E, Van Kesteren H, Zijnen P: Combined therapy with streptokinase and integrilin (abst). J Am Coll 1998; 31 Suppl A: 191A.        [ Links ]

144. Moliterno DJ, Harrington RA, Krukoff MV: For the investigators more complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial. Circulation 1996; 94 Suppl 1:1–553.        [ Links ]

145. Ohman EM, Lincoff AM, Boode C, Candela R, Ellis S, George BI, et al: Trial of abxicimab with and without low–dose reteplasefor infarction acute myocardial. Circulation 2000; 101: 2788–2794.        [ Links ]

146. Herrmann HC, Moliterno DJ, Ohman ME, Stebbins AL, Bode C, Betriu A, et al: Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction (SPEED–GUSTO–4 Pilot Trial). J Am Coll Cardiol 2000; 36: 1489–1496.        [ Links ]

147. Brener SJ, Zeymer U, Adgey JA, Vrobel TR, Ellis SG, Neuhaus KL, et al, for the INTRO AMI investigators: Eptifibatide and low–dose tissue plasminogen activator in acute myocardial infarction (INTRO AMI) Trial. J Am Coll Cardiol 2002; 39: 377.        [ Links ]

148. Grines CL, Booth DC, Nissen SE: Mechanism of acute myocardial infarction in patients with prior coronary artery bypass grafting and therapeutic implications. Am J Cardiol 1990; 65: 1292–1296.        [ Links ]

149. Kleiman NS, Bernan DA, Gastón WR, Cashion WR, Roberts R: Early intravenous thrombolytic therapy for acute myocardial infarction in patients with prior coronary artery bypass grafts. Am J Cardiol 1989; 63: 102–104.        [ Links ]

150. Kavanaugh KM, Topol EJ: Acute intervention during myocardial infarction in patients with prior coronary bypass surgery. Am J Cardiol 1990; 65: 924–926.        [ Links ]

151. Simoons ML, Vos J, Tijssen LPG: Long–term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow–up of an atrial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14: 1609–1615.        [ Links ]

152. Vermeer F, Simoons ML, Bar FW: Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase? Circulation 1986; 74: 1379–1389.        [ Links ]

153. Woodfield SL, Lundergan CF, Reimer JS: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO–I experience. J Am Coll Cardiol 1996; 28: 1661–1669.        [ Links ]

154. TIMI–IIIB Investigators: Effects of tissue–plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non–Q–wave myocardial infarction. Results of the TIMI–IIIB Trial. Circulation 1994; 89: 1545–1556.        [ Links ]

155. Jerjes–Sánchez C, Páez FJR, Arriaga–Nava R, Martínez–Enríquez A: Trombólisis en angina inestable. Una perspectiva antes y después del TIMI IIIB. Arch Inst Cardiol Mex 1996; 66: 254–264.        [ Links ]

156. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, et al: One–year results of the thrombolysis in myocardial infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue–type–plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non–Q wave myocardial infarction. J Am Coll Cardiol 1995; 26: 1643–1650.        [ Links ]

157. Langer A, Goodman SG, Topol EJ, Charlestworth A, Skene AM, Wilcox RG, et al: Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non–Q wave myocardial infarction. J Am Coll Cardiol 1996; 27: 1321–1332.        [ Links ]

158. Jerjes–Sánchez Díaz C: Controversias en los síndromes aterotrombóticos coronarios agudos con desnivel negativo del segmento ST–T. Carlos Jerjes Sánchez–Díaz Autor y Editor. En: Aspectos selectos en urgencias cardiovasculares 2001. 2ª Edición actualizada. México DF. Editorial Vesalio Difusión, 2001, pág. 47–70.        [ Links ]

159. Nagel EL, Fine EG, Krisher JP: Complications of cardio–pulmonary resuscitation. Crit Care Med 1981; 9: 424–425.        [ Links ]

160. Calif RM, Topol EJ, Kereiakes DJ, Abbottsmith CW, George BS, Candela RJ, et al: Cardiac resuscitation should not be a contraindication to thrombolytic therapy for myocardial infarction. Circulation 1988; 78: II–127A.        [ Links ]

161. Tenaglia AN, Califf EM, Candela RJ: Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. Am J Cardiol 1991; 73L: 953–957.        [ Links ]

162. Van Campen LC, Leeuwen GR, Vergheugt FW: Safety and efficacy of thrombolysis for acute myocardial infarction in patients with prolonged out– of–hospital cardiopulmonary resuscitation. Am J Cardiol 1994; 73: 953–958.        [ Links ]

163. Botttger BW, Bode C, Kern S: Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: A prospective clinical trial. Lancet 2001; 357: 1583–1588.        [ Links ]

164. Wang K, Asinger RW, Marriott HJL: ST–segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003; 349: 2128–35.        [ Links ]

165. Sgarbossa EB, Pinski SL, Barbagelata A: Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle–branch block. GUSTO I Investigators. N Engl J Med 1996; 334: 481–484.        [ Links ]

166. Pallares Sodi: Clasificación del infarto del miocardio. Sodi Pallares, Gustavo A. Medrano, Abdo Bisteni, José Ponce de León Jurado. Autores. En: "Electrocardiografía clínica. Análisis deductivo". Instituto Nacional de Cardiología, México DF. Editor Francisco Méndez 1968, pág 186–205.        [ Links ]

167. Huey BL, Beller GA, Kaiser DL, Gibson RS: A comprehensive analysis of myocardial infarction due to right coronary artery and left descending artery occlusion. J Am Coll Cardiol 1988; 12: 1156–1166.        [ Links ]

168. García ML, Jerjes–Sánchez C, Ruiz de Chávez S: Revalidando los criterios de reperfusión no invasivos en pacientes con IAM sometidos a trombólisis farmacológica. (Parte I) Arch Inst Cardiol Mex 1993; 63: 463–478.        [ Links ]

169. García ML, Jerjes–Sánchez C, Ruiz de Chávez S: Revalidando los criterios de reperfusión no invasivos en pacientes con IAM sometidos a trombólisis farmacológica. (Parte II) Arch Inst Cardiol Mex 1993; 63: 563–565.        [ Links ]

170. Lupi–Herrera E, González PH, Juárez HU, Chuquiure E, Vieyra G, Martínez SC: La meta de la reperfusión en los síndromes isquémicos coronarios agudos con elevación del segmento ST. El gran paradigma: lo que hay más allá del flujo TIMI epicárdico: el flujo TIMI 4 miocárdico. Arch Cardiol Mex 2002; 72: 311–349.        [ Links ]

171. De Lemos JA, Braunwald E: ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38: 1283–1294.        [ Links ]

172. Zimebaun PJ, Josephson ME: Use of electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348: 933–940.        [ Links ]

173. López–Sendón J: Troponinas y otros marcadores de daño miocárdico. Mitos y realidades. Rev Esp Cardiol 2003; 56: 16–19.        [ Links ]

174. Ohman ME, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW: Intravenous thrombolysis in acute myocardial infarction. Chest 2001; 119.        [ Links ]

175. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez–Sendón J, for the GRACE Investigators: Practice variation and missed opportunities for reperfusion in ST–segment–elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359: 373–377.        [ Links ]

176. Jerjes–Sanchez C, Arriaga–Nava R, Martinez –Enriquez A: Accelerated versus standard streptokinase infusion in acute myocardial infarction. Chest 1996; 110: 107S.        [ Links ]

177. Neuhaus K, Feuerer W, Jeep–Tebbe, Niederer W, Vogt A, Tebbe U: Improved thrombolysis with a modified dose regimen of recombinant tissue–type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566–1569.        [ Links ]

178. Rappaport E: GUSTO: assessment of the preliminary results. J Myocard Ischemia 1993; 5(8): 15–24.        [ Links ]

179. Hennekens HC, O'Doneell JC, Ridker PM, Marder VJ: Current issues concerning thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1995; 25(Suppl): 18S–22S.        [ Links ]

180. Mark DB, Naylor CD, Hltky MA: Medical resource use and quality of life outcomes following acute myocardial infarction in Canada versus the United States: the Canada–US GUSTO substudy. N Engl J Med 1994; 331: 1130–1135.        [ Links ]

181. Van de Werf F, Barbash G, Amstrong P: Comparison of clinical outcomes in the US and non–US countries participating in GUSTO. Circulation 1993; 88: (Suppl I): 1–507.        [ Links ]

182. Gulba DC, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, et al: Sixty minute alteplase protocol: a new accelerated recombinant tissue–type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1611–1617.        [ Links ]

183. Martínez SC, Domínguez JL, Aguirre SJ, Carrillo J, Chuquiure VE, Franco J, et al: Tratamiento del infarto agudo al miocardio con rt–PA en 60 minutos. Estudio Cooperativo. Arch Inst Cardiol Mex 1997; 67: 126–131.        [ Links ]

184. Baker WF: Thrombolytic therapy: clinical applications. Hematology/oncology Clin North Amer 2003; 17: 1–25.        [ Links ]

185. Jerjes–Sánchez DC: Fibrinólisis farmacológica en el infarto agudo del miocardio con onda Q. Carlos Jerjes Sánchez–Díaz Autor y Editor. En "Aspectos selectos en urgencias cardiovasculares 2001". 2ª Edición actualizada. México DF. Editorial Vesalio Difusión, 2001.        [ Links ]

186. Grines C, DeMaria A: Optimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversies. J Am Coll Cardiol 1990; 16: 223–231.        [ Links ]

187. Cannon CP: Exploring the issues of appropriate dosing in the treatment of acute myocardial infarction: potential benefit of bolus fibrinolytic agents. Am Heart J 2000; 140: S154–S160.        [ Links ]

188. Haire W: Tratamiento de las complicaciones hemorrágicas en las urgencias cardiovasculares. Carlos Jerjes Sánchez–Díaz Autor y Editor. En "Aspectos selectos en urgencias cardiovasculares 2001". 2ª Edición actualizada. México DF. Editorial Vesalio Difusión, 2001, pág. 169–179.        [ Links ]

189. García–Sosa A, Jerjes–Sánchez C, Garza–Ruiz A, Reyes–Cerezo E, Archondo T: El tiempo en la fibrinólisis para infarto agudo: perspectiva de los estudios multicéntricos. Arch Cardiol Mex 2001; 71: S3–106.        [ Links ]

190. Collaborative Group of the Primary Prevention Project (PPP): Low dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 387: 89–95.        [ Links ]

191. Bhatt D, Hirsch A, Ringleb PA, Hacke W, Topol E, on behalf of the CAPRIE investigators: Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead for aspirin. Am Heart J 2000; 140: 67–73.        [ Links ]

192. Scrutinio D, cimminiello C, Marubini E, Pitzalis MV, Di Biase M, Rizzon P, on behalf of the STAMI group: Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001; 37: 1259–1265.        [ Links ]

193. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla–Volta S: Adenosine diphosphate (ADP) induced alfa granules release from platelets of native whole blood is reduced by ticlopidine but not by aspirin or dipyridamole. Thromb Haemost 1986; 56: 147–150.        [ Links ]

194. Savi P, Nurden P, Nurden AT. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251–255.        [ Links ]

195. CAPRIE Steering Committee: A randomized, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.        [ Links ]

196. Van Zanten GH, de Graaf S, Slootweg PJ: Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 1994; 93: 615–632.        [ Links ]

197. Sakariassen KS, Orning L, Stormorken H: Role of ADP and thromboxanes in human thrombus formation in ex vivo models. Platelets 1997; 8: 385–390.        [ Links ]

198. Herbert JM, Dol F, Benat A: The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998; 80:512–518.        [ Links ]

199. Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen K, Boneu B: Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823–2828.        [ Links ]

200. Bertrand M, Rupprecht HJ, Urban P, Gershlick A, for the CLASSICS Investigators: Double–blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000; 102: 624–629.        [ Links ]

200a. Sabatine MS, Cannon CP, Gibson CM, Lopez–Sendon JL, Montalesco G, Theroux P, et al: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST–segment elevation. N Engl J Med 2005; 352(12): 1179–1189.        [ Links ]

201. Collins R, MacMahon S, Flather M, Baigent C, Remvig L, Mortensen S, et al: Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomized trials. Br Med J 1996; 313: 652–659.        [ Links ]

202. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, et al, for the GUSTO I Investigators: The link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: the importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923–1928.        [ Links ]

203. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, et al, and the TAMI Study Group: A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281–286.        [ Links ]

204. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, et al: Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction–a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33: 627–633.        [ Links ]

205. Fitzgerald DJ, Fitzgerald GA: Role of thrombin and thromboxane A2 I reocclusion following coronary thrombolysis with tissue–type plasminogen activator. Proc Natl Acad Sci USA 1989; 86: 7585–7589.        [ Links ]

206. Miletich JP, Jackson CM, Majerus PW: Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci USA 1977; 74: 4033–4036.        [ Links ]

207. Hsia J, Hamilton WP, Kleiman N: A comparison between heparin and low–dose aspirin as adjunctive with tissue plasminogen activator for acute infarction. Heparin–Aspirin Reperfusion Investigators. N Engl J Med 1990; 323: 1433–1437.        [ Links ]

208. De Bono D, Simoons ML, Tijssen J: Effect intravenous heparin on coronary patency, infarct bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122–128.        [ Links ]

209. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 22: 1615–1622.        [ Links ]

210. Giugliano R, McCabe CH, Antman EM: The Thrombolysis in Myocardial Infarction (TIMI) Investigators. Lower dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001; 141: 742–750.        [ Links ]

211. Granger CB, Hirsch J, Califf RM: Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO–I trial. Circulation 1996; 93: 870–878.        [ Links ]

212. Webster MWI, Chesebro JH, Fuster V: Antithrombotic therapy in acute myocardial infarction: enhancement of thrombolysis, reduction of reocclusion and prevention of thromboembolism. En: Gersh BJ, Rahimtolla SH, Eds. Acute myocardial infarction. New York: Elsevier Science Publishing Co. Inc; 1991: 333–348.        [ Links ]

213. Wong GC, Giugliano RP, Antman EM: Use of the low–molecular–weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331–342.        [ Links ]

214. Rosing J, van Rijn JLM, Bevers EM, van Diejen G, Comfurius P, Zwaal RFA, et al: The role of activated human platelets inprothrombin and factor X activation. Blood 1985; 5: 319–332.        [ Links ]

215. Glick A, Kornowski R, Michowich Y: Reduction of reinfarction and angina with use of low–molecular–weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996, 77: 1145–1148        [ Links ]

216. Strandberg LE, Kahan T, Lundin P: Anticoagulant effects of low–molecular–weight heparin following thrombolytic therapy in acute myocardial infarction: a dose–finding study. Haemostasis 1996, 26: 247–257.        [ Links ]

217. The ESPRIM trial: short–term treatment of acute myocardial infarction with molsidomine. European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group. Lancet 1994; 344: 91– 97.        [ Links ]

218. Buffon A, Biasucci LM, Luzzo G, D'Onofrio G, Crea F, Masseri A: Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5–12.        [ Links ]

219. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343: 915–922.        [ Links ]

220. Riofoul G, Finet G, Ginon I, André–Fouët X, Rossi R, Vialle E, et al: Multiple atherosclerotic plaque rupture in acute coronary syndrome. A three–vessel intravascular ultrasound study. Circulation 2002; 106: 804–808.        [ Links ]

221. Hermosillo AG, Dorado M, Casanova M, Ponce de Leon S, Cossio J, Kersenovich S, Colin L, Iturralde P: Influence of infarct–related artery patency on the indexes of parasympathetic activity and prevalence of late potentials in survivors of acute myocardial infarction. J Am Coll Cardiol 1993; 22: 695–706.        [ Links ]

222. The Norwegian Multicenter Study Group: Timolol–induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801–807.        [ Links ]

223. Hjalmarson A, Elmfeldt D, Herlitz: Effect on mortality of metoprolol in acute myocardial infarction, a double–blind randomized trial. Lancet 1981; 2: 823–827.        [ Links ]

224. Beta–Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. 1. Mortality results. JAMA 1982; 247: 1707–1714.        [ Links ]

225. Yusuf S, Lessem J, Jha P: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated controlled trials. J Hypertens 1993;11 l(Suppl 4): S61–73.        [ Links ]

226. Roberts R, Rogers WJ, Mueller HS: Immediate versus deferred beta–blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II–B Study. Circulation 1991; 83: 422–37.        [ Links ]

227. Van de Werf F, Janssens L, Brzostek T, et al: Short–term effects of early intravenous treatment with betaadrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 2: 407–16.        [ Links ]

228. Pfisterer M, Cox JL, Granger CB: Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO–I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 32: 634–640.        [ Links ]

229. Freemantle N, Cleland J, Young P: Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730–1737.        [ Links ]

230. Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac study. (CCS–1) Lancet 1995; 345: 686–687.        [ Links ]

231. Swedberg K, Held P, Kjekshus J, et al: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II. (CONSENSUS II) N Engl J Med 1992; 327: 678–84.        [ Links ]

232. Pfeffer MA, Hennekens CH: When a question has an answer: rationale for our early termination of the HEART trial. Am J Cardiol 1995; 75: 1173–5.        [ Links ]

233. Le Feuvre C, Yusuf S, Flather M, Farkouh M: Maximizing benefits of therapies in acute myocardial infarction. Am J Cardiol 1993; 72: 145G–155G.        [ Links ]

234. Held PH, Yusuf S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. Br Med J 1989; 299:1122–1187.        [ Links ]

235. Yusuf S, Held P, Furberg C: Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAV1T–II) and other recent studies. Am J Cardiol 1991; 67: 1295–1297.        [ Links ]

236. McMahon S, Collins R, Peto R, Koster RW, Yusuf S: Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized controlled trials. JAMA 1988; 260: 1910–1916.        [ Links ]

237. Teo KK, Yusuf S, Collins R: Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomized trials. BMJ 1991; 303: 1499–503.        [ Links ]

238. Woods KL, Fletcher S, Roffe C: Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester intravenous Magnesium Intervention Trial (LIMIT–2). Lancet 1992; 339: 1553–1558.        [ Links ]

239. Antman E: The MAGIC trial, presented at the XXIVth Scientific Sessions of the European Society of Cardiology in Berlin, September 2002.        [ Links ]

240. GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase or both on coronary–artery patency, ventricular function and survival alter acute myocardial infarction. NEJM 1993; 329: 1615–22.        [ Links ]

241. Barron HV, Bowlby LJ, Breen T, et al: Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 1998; 97: 1150–6.        [ Links ]

242. Topol EJ: Coronary angioplasty for acute myocardial infarction. Ann Intern Med 1988; 109: 970–80.        [ Links ]

243. Buller CE, Career RG: New advances in the management of acute coronary syndromes: 3. The role of catheter based procedures. Can Med Assn J 2002; 166:51–61.        [ Links ]

244. Canto JG, Every NR, Magid DJ, et al: The volume of primary angioplasty procedures and survival after acute myocardial infarction: National Registry of Myocardial Infarction 2 Investigators. NEJM 2000; 342: 1573–80.        [ Links ]

245. Rentrop P, Blanke H, Wiegand V, Karsch KR: Wiedereroffnung verschlossener Kranzjefäse im akuten Infarkt mit Hilfe von Kathetern. Transluminale Rekanalisation. Dtsch Med Wochenschr 1979; 104: 1401–1405.        [ Links ]

246. Tamis–Holland JE, Palazzo A, Stebbins AL, Slater JN, Boland J, Ellis SG, Hochman JS: Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II–B) Angioplasty substudy. Am Heart J 2004; 147: 133–199.        [ Links ]

247. Goldenberg I, Matetzky, Halkin A, Roth A, Di Segni E, Freimark D, Elian D, Agranat O, Har Zahav Y, Guetta V, Hod H: Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2003; 145: 862–867.        [ Links ]

248. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13–20.        [ Links ]

249. Zjlistra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van'T Hof AWJ, Suryapranata H: Long term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. NEJM 1999; 341: 1413–1419.        [ Links ]

250. Nunn CM, O'Neil WW, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Grines L, Browne KF, Vlietstra RE, Catlin T, Grines CL: Long term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI–I) trial. J Am Coll Cardiol 1999; 33: 640–646.        [ Links ]

251. Grines CL, Serruys P, O'Neill WW: Fibrinolytic therapy: is it a treatment of the past? Circulation 2003; 107: 2538–2542.        [ Links ]

252. Grines CL, Cox DA, Stone GW, et al: Coronary angioplasty with or without stent implantation foro acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1999; 341: 1949–56.        [ Links ]

253. Stone GW, Grines CL, Cox DA, et al: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346: 957–66.        [ Links ]

254. Cragg DR, Friedman HZ, Bonema JD, et al: Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991; 115: 173–7.        [ Links ]

255. Brodie BR, Weintraub RA, Stuckey TD, et al: Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non–candidates for thrombolytic therapy. Am J Cardiol 1991; 67: 7–12.        [ Links ]

256. Antman E, Guigliano R, Gibson C, et al: Abciximab facilitates the rate and extent of thrombolysis results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720–2732.        [ Links ]

257. GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomized trial. Lancet 2001; 357: 1905–1914.        [ Links ]

258. Assessment of safety and efficacy of a new thrombolytic regimen (ASSENT–3) investigators: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractioned heparin: the ASSENT–3 randomized trial in acute myocardial infarction. Lancet 2001; 358: 605–613.        [ Links ]

259. Martínez RM, Rosas M, González H, Peña MA, Martinez C, Gaspar J: For the SASTRE Investigators. Comparison of reperfusion regimens with or without Tirofiban in ST elevation acute myocardial infarction. Am J Cardiol 2004; 93: 280–287.        [ Links ]

260. Kastrati A, et al: For the BRAVO trial. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention. JAMA 2004; 291: 947–954.        [ Links ]

261. ADVANCE–MI for the TIMI Investigators. Oral presentation AHA New Orleans 2004.        [ Links ]

262. Ellis SG, Armstrong P, Betrew A, Brodie B, Gerrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E: Facilitated percutaneous coronary intervention vs primary percutaneous coronary intervention: Designed and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) Trial. Am Heart J 2004; 147: E16.        [ Links ]

263. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morise MC: For the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895–1903.        [ Links ]

264. Van'T Hoff AW, Ernest N, De Boer MJ, De Winter R, Boersma E, Bun T, Petronio S, Hollak F, Surya Pranata H, Dambrink JH, Zijlstra F: Facilitation of primary coronary angioplasty by early start of a glycoprotein IIb/IIIa Inhibitor: result of the ongoing tirofiban in myocardial infarction evaluation (ON–TIME) trial. Eur Heart J 2004; 25: 837–846.        [ Links ]

265. Lee DP, Herity NA, Hiatt PL, Fearon WF, Rezaee M, Carter AJ, Huston M, Dibatiste PM, Yeng AC: Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the tirofiban given in the emergency room before primary angioplasty (TIGER–PA) pilot trial. Circulation 2003; 107: 1497–1501.        [ Links ]

266. Gydngydsi M, Domanovits H, Benzer W, Haugk M, Heinischb, Sodeckg, Hiodt R, Gaul G, Bonner G, Wojta J, Laggner A, Glogar D, Huber K: Use of abciximab prior to primary angioplasty in STEMI. Results in early recanalization of the infarct–related artery and improved myocardial tissue reperfusion–results of the Austrian multicentre randomized ReoPro–BRIDGING Study. Eur Heart J 2004; 25: 2125–2133.        [ Links ]

267. Montalescot G, Borenstain M, Payot L, Collet JP, Thomas D: Early vs Late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST–Segment elevation myocardial infarction: A meta–analysis. JAMA 2004; 292: 362–366.        [ Links ]

268. Cragg DR, Pritman HZ, Bonema JD, Jaiyesimi IA, Ramos RG, Timmis GC, O'Neal WW, Schreiber TL: Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med 1991; 115: 173–177.        [ Links ]

269. Veermir F, Oudephuts AJ, Vd Berg EJ, Brunninkhutis LG, Werter CJ, Bohemer AJ, Lousberg AH, Dassen WR, Barfw: Prospective randomized comparison between thrombolysis, rescue PTCA and Primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: A safety and feasibility study. Heart 1999; 82:426–431.        [ Links ]

270. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H: Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE Study. Eur Heart J 2000; 21: 823–831.        [ Links ]

271. Widimsky P, Budesinsky T, Vorac D, Groch L, Zelizko M, Aschermannn M, Branny M, St'asek J, Formanek P: Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial–PRAGUE–2. Eur Heart J 2003; 24: 94–104.        [ Links ]

272. Grines CL, Westerhausen DR Jr, Grines LL, Hanlon JT, Logeman TL, Niemela M, Weaver WD, Graham M, Boura J, O'Neal WW, Balestrini C: A randomized trial of transfer for primary angioplasty vs on site thrombolysis in patients with high risk myocardial infarction: The AIR–PAMI angioplasty in myocardial infarction study. J Am Coll Cardiol 2002; 39:1713–1719.        [ Links ]

273. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abildgaard U, Pedersen F, Madsen JK, Grande P: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733–742.        [ Links ]

274. Zijlstra F, Van'T Hof AW, Liem AL, Hoorntje JC, Surya Pranata H, De Boerg MJ: Transferring patients for primary angioplasty: A retrospective analysis of 104 selected high risk patients with acute myocardial infarction. Heart 1997; 78: 333–336.        [ Links ]

275. Schöming AA, Nidrepepa G, Mehilli J, Schwaiger M, Schuhlen H, Nekolla S. Pache J, Martinoff S, Vollwein H, Kastrati A: Therapy–dependent influence of time to treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation 2003; 108: 1084–1088.        [ Links ]

276. Zan R, Schiele R, Gitt AK, Schneider S, Seid K, Voigtlander T, Gottwik M, Altmann E, Gieseler U, Wagner SR: Impact of pre–hospital delay on mortality inpatient with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis. Am Heart J2001; 142: 105–111.        [ Links ]

277. Bonnefoy E, Lapostelle F, Leizorovicz A, Steg G, Mcfaden EP, Dubien PY, Cattan S, Boullenger E, Machecourt J, Lacroutze JM, Casagness J: Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet 2002; 360: 825–829.        [ Links ]

278. Zijlstra F, Patel A, Jones M, Grinnes CL, Ellis S, García E, Grinfeld L, Gibbons RJ, Riveiro E, Ribichini F, Granger C, Weaver WD: For the PCAT collaboration. Clinical characteristics and outcome patients with early (< 2 h), intermediate (2–4 h) and late (> 4 h) presentation treated by primary and coronary angioplasty or thrombolytic therapy por acute myocardial infarction. Eur Heart J 2002; 23: 550–557.        [ Links ]

279. Wu AH, Lane PL: Meta–analysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. Clin Chem 1995; 41: 1228–33.        [ Links ]

280. Ralkilde J, Nissen H, Horder M, Thygesen K: Independent prognostic value or serum creatine kinase isoenzyme MB mass, cardiac troponin T and myosin light chain levels in suspected acute myocardial infarction: analysis of 28 months of follow–up in 196 patients. J Am Coll Cardiol 1995; 25: 574–81.        [ Links ]

281. Grinfeld L, Berrocal D, Belardi J, Spinetta A, Rojas MC, Oberti P, et al: Fibrinolytics vs primary angioplasty in acute myocardial infarction (FAP): a randomized trial in a community hospital in Argentina (abstract). J Am Coll Cardiol 1996; 27 (Suppl A): A–222.        [ Links ]

282. McKendall GR, Forman S, Sopko G, Braunwald E, Williams DO: Value of rescue percutaneous transluminal coronary angioplasty following unsuccessful thrombolytic therapy in patients with acute myocardial infarction. Thrombolysis in Myocardial Infarction Investigators. Am J Cardiol 1995; 76: 1108–11.        [ Links ]

283. Gruberg L, Di Segni E, Agranat O, Har Zahav Y, Freimark D, Kaplinsky E, et al: Rescue coronary angiography after failed thrombolysis: a real–life experience. Cardiology 1998; 90:48–51.        [ Links ]

284. Goldman LE, Eisenberg MJ: Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med 2000; 132: 556–565.        [ Links ]

285. Van deWerf FJ, et al: ASSENT–3 investigators. Assessment of the Safety and Efficacy of a new Thrombolytic regimen. Lancet 2001; 358: 605–613.        [ Links ]

286. Milavetz JJ, Giebel DW, Chistian TF, Schwartz RS, Holmes DR Jr, Gibbons RJ: Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol 1998; 31: 1246–51.        [ Links ]

287. Simoons ML, Arnold AER, Betriu A, De Bono DP, Col J, Dougherty FC, et al: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no addtional benefit from immediate percutaneous coronary angioplasty. Lancet 1998; 1: 197–203.        [ Links ]

288. Liem AL, van't Hof AW, Hoorntje JC, de Boer MJ, Suryapranata H, Zijlstra F: Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infaction treated with primary angioplasty. J Am Coll Cardiol 1998; 32: 629–33.        [ Links ]

289. The TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618–27.        [ Links ]

290. Ellis SG, Da Silva ER, Heyndrickx G, Talley JD, Cernigliaro C, Steg G, et al: Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994; 90: 2280–4.        [ Links ]

291. Belenkie I, Traboulsi M, May CA, Hansen JL, Roth DL, Manyari D, et al: Rescue angioplasty during myocardial infarction has a beneficial effect on mortality: a tenable hypothesis. Can J Cardiol 1992; 8: 357–62.        [ Links ]

292. Califf RM, Topol EJ, Stack RS, Ellis SG, George BS, Kereiakes DJ, et al: Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction phase 5 randomized trial. TAMI Study Group. Circulation 1991; 83: 1543–56.        [ Links ]

293. Ellis SG, Van de Werf F, Ribeiro–daSilva E, Topol EJ: Present status of rescue coronary angioplasty: current polarization of opinion and randomized trials. J Am Coll Cardiol 1992; 19: 681–6.        [ Links ]

294. Outcome of attempted rescue coronary angioplasty after failed thrombolysis For acute myocardial infarction. The CORAMI Study Group: Cohort of Rescue Angioplasty in Myocardial Infarction. Am J Cardiol 1994; 74: 172–4.        [ Links ]

295. Gibson CM, Cannon CP, Greene RM, Sequeira RF, Margorien RD, Leya F, et al: Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial. Am Cardiol 1997; 80: 21–6.        [ Links ]

296. Ross AM, Lundergran CF, Rohrbeck SC, Boyle DH, van den Brand M, Buller CH, et al: Rescue angioplasty after failed thrombolysis: technical and clinical outcome in a large thrombolysis trial; GUSTO–1 angiographic investigators, global utilization of streptolinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol 1998; 31: 1511–7.        [ Links ]

297. Garot P, Himbert D, Juliard JM, Golmard JL, Steg PG: Incidence, consequences, and risk factors of early reocclusion after primary and/or rescue percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1998; 82: 554–8.        [ Links ]

298. Juliard JM, Himbert D, Cristofini P, Desportes JC, Magne M, Golmard JL, et al: A matched comparison of the combination of prehospital thrombolysis and standby rescue angioplasty with primary angioplasty. Am J Cardiol. a chimeric monoclonal antibody (abciximab) on acute and six–month outcomes after percutaneous coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996; 77: 1045–51.        [ Links ]

299. Ellis SG, Da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD: Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction experiences. Am Heart J 2000; 139: 1046–53.        [ Links ]

300. Gibson, et al: TIMI Investigators. J Am Coll Cardiol 2003; 42: 7–16.        [ Links ]

301. Rodriguez AE, Fernandez M, Santaera O, Larribau M, Bernardi V, Castaño H, et al: Coronary stenting in patients undergoing percutaneous transluminal coronary angioplasty during acute myocardial infarction. Am J Cardiol 1996; 77: 685–9.        [ Links ]

302. Moreno R, García E, Abeytua M, Soriano J, Elizaga J, Botas J, López–Sendón JL, Delcan JL: Coronary stenting during rescue angioplasty after failed thrombolysis. Catheter Cardiovasc Interv 1999; 47: 1–5.        [ Links ]

303. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al: Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six–month outcomes after percutaneous coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996; 77: 1045–51.        [ Links ]

304. Upendra K, Rakesh S, Balbir S, Dinesh S, Tapan G, Narayan SD, Harbans SW: Asian Cardiovasc Thorac Ann 2001; 9: 31–35.        [ Links ]

305. Ohman EM, Califf RM, George BS, Quigley PJ, Kereiakes DJ, Harrelson–Woodlief L, et al: The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1991; 121: 895–901.        [ Links ]

306. Ishihara M, Sato H, Tateishi H, Uchida T, Dote K: Intraaortic balloon pumping as the postangioplasty strategy in acute myocardial infarction. Am Heart J 1991; 122: 385–9.        [ Links ]

307. Ohman EM, George BS, White CJ, Kern MJ, Gurbel PA, Freedman RJ, et al: Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Results of a randomized trial. The Randomized IABP Study Group. Circulation 1994; 90: 792–9.        [ Links ]

308. Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, et al: A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI–II) Trial Investigators. J Am Coll Cardiol 1997; 29: 1459–67.        [ Links ]

309. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, et al: Intraaortic balloon pumping as an adjunctive therapy to rescue coronary angioplasty after failed thrombolysis in anterior wall myocardial infarction. Am J Cardiol 1995; 76: 73–5.        [ Links ]

310. Hong YJ, Jeong MH, Lee SH, Park OY, Jeong WK, Lee SR, Kim W, Rhew JY, Lee SH, Ahn YK, Cho JG, Ahn BH, Park JC, Kim SH, Kang JC: Long term clinical outcomes after rescue percutaneous coronary intervention in patients with acute myocardial infarction. J Interv Cardiol 2003; 16: 209–16.        [ Links ]

311. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, et al: A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581–8.        [ Links ]

312. Simoons ML, Bertiu A, Arnold AER, de Bono DP, von Essen R, Lambertz H: Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1: 197–203.        [ Links ]

313. TIMI Research Group: Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI IIA results. JAMA 1988; 260: 2849–58.        [ Links ]

314. Scheller B, Hennen B, Hammer B, Walle J, Hofer C, Hilpert V, et al: Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 634–41.        [ Links ]

315. TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Acute Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618–27.        [ Links ]

316. Williams DO, Braunwald E, Knatterud G, Babb J, Bersnahan J, Greenberg MA, et al: One–year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) phase II. Circulation 1992; 85: 533–42.        [ Links ]

317. SWIFT Trial Study Group: SWIFT trial of delayed elective intervention vs conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. Br Med J 1991; 302: 555–60.        [ Links ]

318. Madsen JK, Grande P, Saunamäki K, Thayssen P, Kassis E, Eriksen U, et al: Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997; 96: 748–755.        [ Links ]

319. White HD, Cross DB, Elliott JM, et al: Long–term prognostic importance of patency of the infarct–related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89: 61–7.        [ Links ]

320. Abbate A, Bussani R, Biondi–Zoccai GC, Rossiello R, Silvestri F, Baldi F, Biasucci LM, Baldi A: Persistent infartc–related artery occlusion is associated with an increased myocardial apoptosis at postmortem examination in humans late after acute myocardial infarction. Circulation 2002; 106: 1051–4.        [ Links ]

321. Fibrinolytic Therapy Trialists Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet 1994; 343: 311–22.        [ Links ]

322. Braunwald E: Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation 1989; 79:441–4.        [ Links ]

323. Fortin DF, Califf RM: Long–term survivalfrom acute myocardial infarction: salutary effect of an open coronary vessel. Am J Med 1990; 88: 9–15N.        [ Links ]

324. Sadanandan S, Buller C, Menon V, Dzavik V, Terrin M, Thompson B, Lamas G, Hochman JS: The late open artery hypothesis–a decade later. Am Heart J 2001; 142:411–21.        [ Links ]

325. Puma JA, Sketch MH, Thompson TD, Simes RJ, Morris DC, White HD, Topol EJ, Califf RM: Support for the open–artery hypothesis in survivors of acute myocardial infarction: Analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol 1999; 83: 482–487.        [ Links ]

326. Leung W, Lau C: Effects of severity of the residual stenosis of the infarct related coronary artery on left ventricular dilation and function after acute myocardial infarction. J Am Coll Cardiol 1992; 20: 307–13.        [ Links ]

327. Dzavik V, Beanlands D, Leddy D, Davies RF, Kimber S: Does late revascularization alter the evolution of the signal–averaged electrocardiogram in patients with a recent transmural myocardial infarction? Can J Cardiol 1995; 11: 378 84.        [ Links ]

328. Lamas GA, Flaker GC, Mitchel G, Smith SC, Gersh B J, Wun C, et al: Effect of artery patency on prognosis after acute myocardial infarction. Circulation 1995; 92: 1101–9.        [ Links ]

329. Ellis SG, Mooney MR, George BS, da Silva EE, Talley JD, Flanagan WH, Topol EJ: Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post–Thrombolytic Stenoses (TOPS) Study Group. Circulation 1992; 86: 1400–6.        [ Links ]

330. Yousef ZR, Redwood SR, Bucknall CA, Sulke AN, Marber MS: Late intervention after anterior myocardial infarction: Effects on left ventricular size, function, quality of life, and exercise tolerance. Results of the Open Artery Trial (TOAT) Study. J Am Coll Cardiol 2002; 40: 869–76.        [ Links ]

331. Zeymer U, Uebis R, Vogt A, Glunz HG, Vöhringer HF, Harmjanz D, Neuhaus KL: Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease. A study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte. Circulation 2003; 108: 1324–8.        [ Links ]

332. Bosch X, Theroux P, Walters D, Pelletier G, Roy D: Early post–infarction ischemia: clinical, angiographic and prognostic significance. Circulation 1987; 75: 988–995.        [ Links ]

333. Figueras J, Cinca J, Valle V, Rius J: Prognostic implications of early spontaneous angina after acute myocardial infarction. Int J Cardiol 1983; 4: 461–472.        [ Links ]

334. Sellier P, Plat F, Corona P, Payen B, Audouin P, Ourbak P: Prognostic significance of angina pectoris, recurring soon after myocardial infarction. Eur Heart J 1988; 9: 447–453.        [ Links ]

335. Galjee MA, Visser FC, De Cock CC, Van Eenige MJ: The Prognostic value, clinical and angiographic characteristics of patients with early post–infarction angina after a first myocardial infarction. Am J Cardiol 1987; 59: 241–244.        [ Links ]

336. Antman EM: General hospital management. En: Julian DG, Braunwald E, eds. Management of Acute Myocardial Infarction. London, England: WB Saunders Co. Ltd; 1994: 42–44.        [ Links ]

337. Weisman HF, Healy B: Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis 1987; 30: 73–110.        [ Links ]

338. Hutchins GM, Bulkley BH: Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978; 41: 1127–1132.        [ Links ]

339. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease: I. treatments following myocardial infarction. JAMA 1988; 260: 2088–2093.        [ Links ]

340. El Registro Nacional de los Síndromes Isquémicos Coronarios Agudos (RENASICA). Sociedad Mexicana de Cardiología. Por el Grupo cooperativo RENASICA. Arch Cardiol Mex 2002; 72 (Supl 2): 45–64.        [ Links ]

341. Betrium A, Califa RM, Bosch X, Guerci A, Stebbins A, et al: For the GUSTO–I Investigators. Recurrent Ischemia AFTER Thrombolisis: Importance of Associated Clinical Findings. J Am Coll Cardiol 1998; 31: 94–102.        [ Links ]

342. The Platelet Receptor Inhibition in Isquemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM–PLUS) study investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non–Q–wave myocardial infarction. N Engl J Med 1998; 338: 1488–1497.        [ Links ]

343. Califa RM: Acute myocardial infarction. En: Smith TW. Editor. Cardiovascular therapeutics. Philadelphia: WB Saunders Company, 1996.        [ Links ]

344. Corner F, Romero C, Ribas M, Quintana E, Barthe J, Gauss C, et al: Utilitat del baló de contrapulsació intraaórtica en I'angina refractaria severa. Rev Soc Catalana Cardiol 1995; 1: 10.        [ Links ]

345. Purvis JA, McNeil AJ, Roberts MJD, Dalzell GW, Wilson CM, Campbell NP, et al: First–yearfollow–up after repeat thrombolytic therapy with recombinant–tissue plasminogen activator for myocardial reinfarction. Coronary Artery Dis 1992; 3: 713–720.        [ Links ]

346. Oliva PB, Hammill SC, Talano JV: Effect of definition on incidence of postinfarction pericarditis: is it time to redefine postinfarction pericarditis? Circulation. 1994; 90: 1537–1541.        [ Links ]

347. Tofler GH, Muller JE, Stone PH, et al: Pericarditis in acute myocardial infarction: characterization and clinical significance. Am Heart J 1989; 117: 86–92.        [ Links ]

348. Wall TC, Califf RM, Harrelson–Woodlief L, et al: Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage: the TAMI Study Group. Am J Cardiol 1990; 66: 1418–1421.        [ Links ]

349. Spodick DH: Pericardial complications of myocardial infarction. En: Francis GS, Alpert JS, editors. Coronary Care. Boston: Little. Brown and Co. 1995:333.        [ Links ]

350. Oliva PB, Hammill SC: The clinical distinction between regional postinfarction pericarditis and other causes of postinfarction chest pain: ancillary observations regarding the effect of lytic therapy upon the frequency of postinfarction pericarditis, postinfarction angina, and reinfarction. Clin Cardiol 1994; 17: 471–478.        [ Links ]

351. Berman J, Haffajee CI, Alpert JS: Therapy of symptomatic pericarditis after myocardial infarction: retrospective and prospective studies of aspirin, indomethacin, prednisone, and spontaneous resolution. Am Heart J 1981; 101:750–753.        [ Links ]

352. Lilavie CJ, Gersh PJ: Mechanical and electrical complication of acute myocardial infarction. Mayo Clin Proc 1990; 65: 709–730.        [ Links ]

353.Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico, GISSI–2: afactorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71.        [ Links ]

354. The International Study Group: In–hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparina. Lancet 1990; 336: 71–75.        [ Links ]

355. Rott D, Echar S, Gottlicb S, Boyko V, Hod H: Usefulness of the Killip classification for early risk stratification of patients with acute myocardial infarction in the 1980s. Am J Cardiol 1997; 80: 859–64.        [ Links ]

356. Miller WL, Wright RS, Grill JP, Kopeeky SL: Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin Cardiol 2000; 23: 751–758.        [ Links ]

357. Emanuelsson H, Karlson BW, Herlitz J: Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. Eur Heart J 1994; 15:761–768.        [ Links ]

358. Zornoff L, Skali H, Pfeffer MA, Sutton M, Rouleau J, et al: Right Ventricular Dysfunction and Risk of Heart Failure and Mortality After Myocardial Infarction. J Am Coll Cardiol 2002; 39: 1450–5.        [ Links ]

359. Marmor A, Geltman EM, Biello DR, Sobel BE, Siegel BA, Roberts R: Functional response of the right ventricle to myocardial infarction: dependence on the site of left ventricular infarction. Circulation 1981; 64: 1005–1011.        [ Links ]

360. Rigolin VH, Robiolio PA, Wilson JS, Harrison JK, Bashore TM: The forgotten chamber: the importance of the right ventricle. Cathet Cardiovasc Diagn 1995; 35: 18–28.        [ Links ]

361. Pfisterer M, Emmenegger H, Soler M, Burkart F: Prognostic significance of right ventricular ejection fraction for persistent complex ventricular arrhythmias and/or sudden death after first myocardial infarction: relation to infarct location, size and left ventricular function. Eur Heart J 1986; 7: 289–298.        [ Links ]

362. Gadsboll N, Hoilund–Carlsen PF, Madsen EB, et al: Right and left ventricular ejection fractions: relation to one–year prognosis in acute myocardial infarction. Eur Heart J 1987; 8: 1201–1209.        [ Links ]

363. Mehta SR, Eikelboom JW, Natarajan MK, et al: Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. J Am Coll Cardiol 2001; 37: 37–43.        [ Links ]

364. Zehender M, Kasper W, Kauder E, et al: Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993; 328: 981–988.        [ Links ]

365. Killip T, Kimball JT: Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. AM J Cardiol 1967; 20: 457–64.        [ Links ]

366. Forrester JS, Diamond G, Chatterjee K, Swan HJ: Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 1976; 295: 1.356–1.362        [ Links ]

367. Hochman JS, Boland J, Sleeper LS, Porway M, Brinker J, Col J, et al: Current spectrum of cardiogenie shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 1995; 91: 873–81.        [ Links ]

368. Goldberg RJ, Gore JM, Alpert JS, Osganian V, deGroot J, Bade J, et al: Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community–wide perspective, 1975 to 1988. N Engl J Med 1991; 325: 1117–22.        [ Links ]

369. Ryan TJ, Anderson JL, Antman EM, et al : ACC/ AHA Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1328–1428.        [ Links ]

370. Menon V, Webb JG, Hillis LD, et al, for the SHOCK Investigators: Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36: 1110–6.        [ Links ]

371. Scheidt S, Ascheim R, Killip T 3d: Shock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol 1970; 26: 556–64.        [ Links ]

372. Hands ME, Rutherford JD, Muller JE, Davies G, Stone PH, Parker C, et al: The in–hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol 1989; 14: 40–6.        [ Links ]

373. Leor J, Goldbourt U, Reicher–Reiss H, Kaplinsky E, Behar S: Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med 1993; 94: 265–73.        [ Links ]

374. Becker RC, Gore JM, Lambrew C, Weaver WD, Rubison RM, French WJ, Tiefenbrunn AJ, Bowlby LJ, Rogers WJ: A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol 1996; 27: 1321–1326.        [ Links ]

375. Tuttle RR, Mills J: Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36: 185–96.        [ Links ]

376. Gillespie TA, Ambos HD, Sobel BE, Roberts R: Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39: 588–94.        [ Links ]

377. Keung EC, Siskind SJ, Sonneblick EH, Ribner HS, Schwartz WJ, LeJemtel TH: Dobutamine therapy in acute myocardial infarction. JAMA 1981; 245: 144–6.        [ Links ]

378. Holzer J, Karliner JS, O'Rourke RA, Pitt W, Ross J Jr: Effectiveness of dopamine in patients with cardiogenic shock. Am J Cardiol 1973; 32: 79–84.        [ Links ]

379. Goldberg LI, Hsieh YY, Resnekov L: Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine. Prog Cardiovasc Dis 1977; 19: 327–40.        [ Links ]

380. Richard C, Ricome JL, Rimailho A, Bottineau G, Auzepy P: Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation 1983; 67: 620–6.        [ Links ]

381. Moyer J, Skelton J, Mills L: Norepinephrine: effect in normal subjects; use in treatment of shock unresponsive to other measures. Am J Med 1953; 15: 330–43.        [ Links ]

382. Hollenberg SM, Hoyt J: Pulmonary artery catheters in cardiovascular disease. New Horiz 1997; 5: 207–13.        [ Links ]

383. Hochman J: Cardiogenic shock. Annual Scientific Sessions, American Heart Association. Dallas, TX; 1998.        [ Links ]

384. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo–controlled clinical trial. AIMS Trial Study Group. Lancet 1988; 1: 545–9.        [ Links ]

385. Sanborn TA, Sleeper LA, Bates ER, et al, for the SHOCK Investigators: Impact of thrombolysis, aortic counterpulsation, and their combination in cardiogenic shock: a report from the SHOCK Trial Registry. J Am Coll Cardiol 2000; 36: 1123–9.        [ Links ]

386. Stomel RJ, Rasak M, Bates ER: Treatment strategies for acute myocardial infarction complicated by cardiogenic shock in a community hospital. Chest 1994; 105: 997–1002.        [ Links ]

387. Barron HV, Pirzada SR, Lomnitz DJ, Every NR, Gore JM, Chou TM: Use of intra–aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock (abstr). J Am Coll Cardiol 1998; 31(Suppl A): 135A.        [ Links ]

388. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78: 35–40.        [ Links ]

389. Scheidt S, Wilner G, Mueller H, et al: Intra–aortic balloon counterpulsation in cardiogenic shock: report of a cooperative clinical trial. N Engl J Med 1973; 288: 979–984.        [ Links ]

390. Leinbach RC, Gold HK, Harper RW, Buckley MJ, Austen WG: Early intraaortic balloon pumping for anterior myocardial infarction without shock. Circulation 1978; 58: 204–210.        [ Links ]

391. Sammel NL, O'Rourke MF: Arterial counterpulsation in continuing myocardial ischaemia after acute myocardial infarction. Br Heart J 1979; 42: 579–582.        [ Links ]

392. DeWood MA, Notske RN, Hensley GR, et al: Intraaortic balloon counterpulsation with and without reperfusion for myocardial infarction shock. Circulation 1980; 61: 1105–1112.        [ Links ]

393. Cohn LH: Surgical management of acute and chronic cardiac mechanical complications due to myocardial infarction. Am Heart J 1981; 102: 1049–1060.        [ Links ]

394. Levine FH, Gold HK, Leinbach RC, Daggett WM, Austen WG, Buckley MJ: Management of acute myocardial ischemia with intraaortic balloon pumping and coronary bypass surgery. Circulation 1978; 58(Suppl I): I–69–I–72.        [ Links ]

395. Bregman D, Casarella WJ: Percutaneous intraaortic balloon pumping: initial clinical experience. Ann Thorac Surg 1980; 29: 153–155.        [ Links ]

396. Subramanian VA, Goldstein JE, Sos JA, Et Al: Preliminary clinical experience with percutaneous intra–aortic balloon pumping. Circulation 1980; 62(Suppl I): 1123–9.        [ Links ]

397. Ohman EM, George BS, White CJ, et al: Use of aortic counterpulsation to improve sustained coronary artery patency during acute myocardial infarction. Circulation 1994; 90: 792–799.        [ Links ]

398. Voudris V, Marco J, Morice M, et al: "High–risk" percutaneous transluminal coronary angioplasty with preventive intra–aortic balloon counterpulsation. Cathet Cardiovasc Diagn 1990; 19: 160–164.        [ Links ]

399. Urschel CW, Eber L, Forrester J, Matloff J, Carpenter R, Sonnenblick E: Alteration of mechanical performance of the ventricle by intraaortic balloon counterpulsation. Am J Cardiol 1970; 25: 546–551.        [ Links ]

400. Weber KT, Janicki JS: Intraaortic balloon counterpulsation: a review of physiologic principles, clinical results and device safety. Ann Thorac Surg 1994; 17: 602–636.        [ Links ]

401. Lee L, Erbel R, Brown TM, Laufer N, Meyer J, O'Neill WW: Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long–term survival. J Am Coll Cardiol 1991; 17: 599–603.        [ Links ]

402. Bengtson JR, Kaplan AJ, Pieper KS, et al: Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992; 20: 1482–1489.        [ Links ]

403. Stone GW, Marsalese D, Brodie BR, et al: A prospective, randomized evaluation of prophylactic intra–aortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI–II) Trial Investigators. J Am Coll Cardiol 1997; 29: 1459–67.        [ Links ]

404. Busch T, Sirbu H, Zenkel D, Dalichau H: Vascular complications related to intra–aortic balloon counterpulsation: an analysis of ten years experience. Thorac Cardiovasc Surg 1997; 45: 55–9.        [ Links ]

405. Stone GW, Ohman EM, Millar M, Christenson J, et al: Contemporary Utilization and outcome of Intra–Aortic Balloon Counterpulsation in Acute Myocardial Infarction. The Benchmark Registry. J Am Coll Cardiol 2003; 41: 1940–5.        [ Links ]

406. Hoschman JS, Sleeper LA, Webb JG, et al: The should we emergently revascularize Occluded Coronarles for cardiogenlc shock? (SHOCK) Investigators. Early revascularization in acute myocardial Infarction complicated by cardiogenlc shock. N Engl J Med 1999; 341: 625–34.        [ Links ]

407. Mahmarlan JJ, Marhmarlan AC, Marks GF, et al: Role of adenosine thallium–201 tomography for defining long–term risk in patients after acute myocardial infarction. J Am Coll Cardiol 1995; 25: 1333–40.        [ Links ]

408. Jacobs AK, Leopold JA, Bates E, Mendes L, Sleeper L, et al: Cardiogenic SOC Caused by Right Ventricular Infarction. A Report From the SHOCK Registry. J Am Coll Cardiol 2003; 41: 1273–9.        [ Links ]

409. Braat SH, Ramentol M, Halders S, Wellens HJ: Reperfusion with streptokinase of an occluded right coronary artery: effects on early and late right and left ventricular ejection fraction. Am Heart J 1987; 113: 257–260.        [ Links ]

410. Love JC, Haffajee CI, Gore JM, Alpert JS: Reversibility of hypotension and shock by atrial or atrioventricular sequential pacing in patients with right ventricular infarction. Am Heart J 1984; 108: 5–13.        [ Links ]

411. Fein F, Scheur J: Heart disease in diabetes mellitus: theory and practice. En: Rifkin H, Porte D Jr., editors. New York: Elsevier, 1990: 812–23.        [ Links ]

412. Multiple Risk Factor Intervention Trial Research Group: Stamler J, Vaccaro O, Neaton JD and Wentworth D: Diabetes, other risk factors and 12–year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444.        [ Links ]

413. Wingard DL, Barrett–Connor E: Heart disease and diabetes. En: National Diabetes Data Group. Diabetes in America. 2^nd edition. Washington DC: Government Printing Office, 1995: 429–48. (NIH publication number 95–1468).        [ Links ]

414. Kannel W: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100–1107.        [ Links ]

415. Jacoby RM, Nesto RW: Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992; 20: 736–744.        [ Links ]

416. GUSTO–I Investigators Mak KH, Moliterno DJ and Granger CB et al: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30: 171–179.        [ Links ]

417. GISSI–2 Investigators Zuanetti G, Latini R, Maggioni AP, Santoro L and Franzosi PG: Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI–2 study. J Am Coll Cardiol 1993; 22: 1788–1794.        [ Links ]

418. SAVE Investigators Pfeffer MA, Moyé LA and Braunwald E et al: Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991; 266: 528–532.        [ Links ]

419. Fragmin during Instability in Coronary Artery Disease (FRISC) study group: Low–molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561–568.        [ Links ]

420. FRIC Investigators Klein W, Buchwald A and Hillis SE et al: Comparison of low–molecular–weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of instable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61–68.        [ Links ]

421. Bernink PJLM, Antman EM, McCabe CH, et al: Treatment benefit with enoxaparin in unstable angina is greatest in patients at highest risk: A multivariate analysis from TIMI 11B. J Am Coll Cardiol 1999; 33(Suppl. A): 352A (abstr).        [ Links ]

422. EPISTENT Investigators: Randomized placebo–controlled and bailoon–angioplasty–controlled trial to assess safety of coronary stenting with use of platelet glycoprotein–IIb/IIIa blockade. Lancet 1998; 352: 87–92.        [ Links ]

423. EPISTENT Investigators Marso SP, Lincoff AM and Ellis SG et al: Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic study. Circulation 1999; 100: 2477–2484.        [ Links ]

424. Higgs ER, Parfitt VJ, Harney BA, Harlog M: Use of thrombolysis for acute myocardial Infarction in the presence of diabetic retinopathy in the UK, and associated ocular haemorrhagic complications. Diabetic Med 1995; 12: 426–428.        [ Links ]

425. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J: Beta–blockers and sudden cardiac death. Ann Intern Med 1995; 123: 358–367.        [ Links ]

426. Zuanetti G, Latini R, Maggioni AP, et al: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI–3 study. Circulation 1997; 96: 4239–4245.        [ Links ]

427. Survival of Myocardial Infarction Long–term Evaluation (SMILE) Study Investigators Ambrosioni E, Borghi C and Magnani B: The effect of the angiotensin–converting–enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80–85.        [ Links ]

428. DIGAMI Study Group Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenström A and Wedel H: Effects of insulin treatment on cause–specific one–year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996; 17: 1337–1344.        [ Links ]

429. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long–term results from the Diabetes and Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation 1999; 99: 2626–2632.        [ Links ]

430. Maggioni AP, Maseri A, Fresco C, et al, on behalf of the Investigators of the Gruppo Italiano per lo Studio della Sopravivenza nell' Infarto Miocardico (GISSI–2): Age–related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. N Engl J Med 1993; 329: 1442–1448.        [ Links ]

431. Devlin W, Cragg D, Jacks M, Friedman H, O'Neill W, Grines C: Comparison of outcome in patients with acute myocardial infarction aged > 75 years with that in younger patients. Am J Cardiol 1995; 75: 573–576.        [ Links ]

432. Maynard C, Every NR: Thrombolysis versus primary angioplasty in older patients with acute myocardial infarction. Drugs Aging 1999; 14: 427–435.        [ Links ]

433. Haase KK, Schiele R, Wagner S, et al: In-hospital mortality of elderly patients with acute myocardial infarction: data from the MITRA (Maximal Individual Therapy in Acute myocardial infarction) registry. Clin Cardiol 2000; 23: 831–836.        [ Links ]

434. Hannan EL, Racz MJ, Arani DT, Ryan TJ, Walford G, McCallister BD: Short– and long–term mortality for patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1194–1201.        [ Links ]

435. Klein L, Meter B, Brindis RG, MCKay C, et al: Percutaneous Coronary Intervention in Octagenarians in the American College of Cardiology–National Cardiovascular Data Registry. J AM Coll Cardiol 2002; 40: 394–402.        [ Links ]

436. Grines CL, Browne KF, Marco J, et al, for the Primary Angioplasty in Myocardial Infarction Study Group: A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673–679.        [ Links ]

437. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H: A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680–684.        [ Links ]

438. Gibbons RJ, Holmes DR, Reeder GS, Bayley KR, Hopfenspirger MR, Gersh BJ: Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685–691.        [ Links ]

439. Batchelor WB, Anstrom KJ, Muhlbaier LH, et al: Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. J Am Coll Cardiol 2000; 36: 723–730.        [ Links ]

440. Cowan JC, Gardiner P, Reid DS: A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating acute myocardial infarction. J Cardiac Phamacol 1986; 8: 252–256        [ Links ]

441. Koster RW, Dunning AJ: Intramuscular Lidocaine For Prevention of lethal arrythmias in the prehospitalization fase of acute myocardial infarction. N Engl J Med 1985; 313: 1105–10.        [ Links ]

442. Kober L: Diamond Study Group. A clinic trial of dofetilide in patients with acute myocardial infarction and left ventricular dysfunction. The Diamond MI Study. Circulation 1998; 98: 1–93.        [ Links ]

443. La Rovere M, Bigger JT, Marcus FI, et al, for the ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators: Baroreflex sensitivity and heart–rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998; 351: 478–484.        [ Links ]

444. Moss AJ, Hall WJ, Cannom DS, et al: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996,335: 1933–1940. (MA–DIT I).        [ Links ]

445. Buxton AE, Lee KL, Fisher JD, et al: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators (MUSTT). N Engl J Med 1999; 341: 1882–1890.        [ Links ]

446. Bigger JT Jr: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary–artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337: 1569–1575.        [ Links ]

447. Moss AJ, Zareba W, Hall WJ, et al: The Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. (MADIT II). N Engl J Med 2002; 346: 877–883.        [ Links ]

448. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, Dicarlo L, DeMets D, White BG, DeVries DW, Feldman AM, for the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators: Cardiac–resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–2150.        [ Links ]

449. Kadish A, Dyer A, Daubert JP, Quigg R, Estes M, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy (DEFINITE). N Engl J Med 2004; 350:2151–2158.        [ Links ]

450. Hohnloser SH, Connolly SJ, Kuck KH, Dorian P, Fain E, Hampton JR, Hatala R, Pauly AC, Roberts RS, Themeles EBA, Gent M, for the DINAMIT Investigators: The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): Study protocol. American Heart Journal 2000; 140(5): 735–739.        [ Links ]

451. Dorian P, Connolly S, Hohnloser S: DINAMIT: Defibrillator in acute myocardial infarction trial. Presentation at Heart Rhythm 2004 Annual Scientific Sessions, May 22, 2004.        [ Links ]

452. Mohr R, Moshkovitch Y, Shapira I, Amir G, Hod H, Gurevitch J: Coronary artery bypass without cardiopulmonary bypass for patients with acute myocardial infarction. J Thorac Cardiovasc Surg 1999; 118(1): 50–6.        [ Links ]

453. Albes JM, Gross M, Franke U, Wippermann J, et al: Revascularization during acute myocardial infraction: risks and benefits revisited. Ann Thorac Surg 2002: 74: 102–8.        [ Links ]

454. Creswell LL, Moulton MJ, Cox JL, Rosenbloom M: Revascularization after acute myocardial infarction. Ann Thorac Surg 1995; 60(1): 19–26.        [ Links ]

455. Hochberg MS, Parsonnet V, Gielchinsky I: Timing of coronary revascularization after acute myocardial infarction. Early and late results in patients revascularizated within seven weeks. J Thorac Cardiovasc Surg 1984; 88(6): 914–21.        [ Links ]

456. Stone GW, Brodie BR, Griffin JJ, Grines J, O'Neill WW, Grines CL: Role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute myocardial infarction. Am J Cardiol; 85(11): 1292–6.        [ Links ]

457. Crossman AW, DÁgostino HJ, Geraci SA: Timing of coronary graft surgery following a myocardial infarction: a critical literature review. Clin Cardiol 2002; 25(9): 406–10.        [ Links ]

458. Every NR, Maynard C, Cochran RP, Martin J, Weaver WD: Characteristics, Management, and outcome of patients with acute myocardial infraction trated with bypass surgery. Myocardial infraction triage and intervention investigators. Circulation 1996; 94(9 suppl): 1181–6.        [ Links ]

459. Gibbons RJ, Kanu Chatterjee K, Daley J, Douglas JS, et al: ACC/AHA/ACP–ASIM Guidelines for the Management of Patients With Chronic Stable Angina: Executive Summary and Recommendations. Circulation 1999; 99: 2829–2848.        [ Links ]

460. Maseri A, Chierchia S, Davies G, et al: Pathophysiology of coronary occlusion in acute infarction. Circulation 1986; 73: 233–239.        [ Links ]

461. Alonso JJ, Azpitarte J, Bardaji A, et al: Guías de práctica clínica de la Sociedad Española de Cardiología en Cirugía Coronaria. Rev Es Cardiol 2000; 53(2): 241–66.        [ Links ]

462. Locker C, Mohr R, Paz J, et al: Myocardial revascularization for acute myocardial infarction: benefits and drawbacks of avoiding cardiopulmonary bypass. Ann Thorac Surg 2003; 76: 771–7.        [ Links ]

463. Rayan TJ, Antman EM, Brooks MH, Califf RM, et al: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. American College of Cardiology 1999:3–71.        [ Links ]

464. Braunwald E, Antman EM, Beasley JW, et al: ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST–Segment Elevation Myocardial Infarction: Executive Summary and Recommendations. Circulation 2000; 102: 1193–1209.        [ Links ]

465. Eagle KA, Guyton RA, Davidoff R, et al: ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery. JACC 1999; 34(4): 1262–347.        [ Links ]

466. Pretre R, Ye Q, Grunenfelder J, Zund G, Turina MI: Role of myocardial revascularization in postinfarction ventricular septal rupture. Ann Thorac Surg 2000; 69(1): 51–5.        [ Links ]

467. Tashiro T, Todo K, Haruta Y, Yasunaga H, Shibano R, Kawara T: Extended endocardial repair of postinfarction ventricular septal rupture: new operative technique–modification of the Komeda–David operation. J Card Surg 1994; 9(2): 97–102.        [ Links ]

468. Birnbaum Y, Chamoun AJ, Anzuini A, Lick SD, Ahmad M, Uretsky BF: Ventricular free wall rupture following acute myocardial infarction. Coron Artery Dis 2003; 14(6): 463–70.        [ Links ]

469. Birnbaum Y, Chamoun AJ, Conti VR, Uretsky BF: Mitral regurgitation following acute myocardial infarction. Coron Artery Dis 2002; 13(6): 337–44.        [ Links ]

470. Christ G, Siostrzonek P, Maurer G, Baumgartner H: Partial papillary muscle rupture complicating acute myocardial infarction. Eur Heart J1995; 16(11): 1736–8.        [ Links ]

471. Loisance DY, Lordez JM, Deleuze PH, Dubois–Rande JL, Lellouche D, Cachera JP: Acute postinfarction septal rupture: long–term results. Ann Thorac Surg 1991; 52(3): 474–8.        [ Links ]

472. Blanche C, Khan SS, Matloff JM, Chaux A, DeRobertis MA, Czer LS, Kass RM, Tsai TP: Results of early repair of ventricular septal defect after an acute myocardial infarction. J Thorac Cardio vase Surg 1992; 104(4): 961–5.        [ Links ]

473. Holmes DR: Cardiogenie shock: a lethal complication of acute myocardial infarction. Rev Cardiovasc Med 2003; 4(3): 131–5.        [ Links ]

474. Safi AM, Rachko M, Kwan T, Tang A, Stein RA: Dynamic left ventricular outflow obstruction: a reversible mechanical complication of acute myocardial infarction. Angiology 2002; 53(6): 721–6.        [ Links ]

475. Mesa GJM, Aroca PA, Ramirez VU, Rubio MA, Gallego P, Moreno I, Oliver RJM: Surgery of mechanical complications of acute myocardial infarct. Rev Esp Cardiol 1998; 51(Suppl 3): 71–9.        [ Links ]

476. Muller I, Andrassy P, Firschke C: Left ventricular pseudoaneurysm: a mechanical complication of acute myocardial infarction. Heart 2002; 87(6): 569.        [ Links ]

477. Reeder GS: Identification and treatment of complications of myocardial infarction. Mayo Clin Proc 1995; 70(9): 880–4.        [ Links ]

478. Dzavik V, Sleeper LA, Cocke TP, et al: Early revascularization is associated with improved survival ederly patients with acute myocardial infarction complicated with cardio genie shock: a report from the SHOCK trial registry. Eur Heart J 2003; 24(9): 828–37.        [ Links ]

479. Crossman AW, D'Agostino HJ, Geraci SA: Timing of coronary artery bypass graft surgery following acute myocardial infarction: a critical literature review. Clin Cardiol. 2002; 25(9): 406–10.        [ Links ]

480. Braxton JH, Hammond GL, Letsou GV, et al: Optimal timing of coronary artery bypass graft surgery after acute myocardial infarction. J Thorac Cardiovasc Surg 2003; 125(1): 115–9.        [ Links ]

481. Sintek CF, Pfeffer TA, Khonsari S: Surgical revascularization after acute myocardial infarction. Does timing make a difference? Am J Cardiol 2002; 90(1): 35–8.        [ Links ]

482. Kaul TK, Fields BL, Riggins SL, Dacumos GC, Wyatt DA, Jones CL: Coronary artery bypass graftin within 30 days an acute myocardial infarction. Ann Thorac Surg 1995; 59(5): 1169–76.        [ Links ]

483. Chatterjee K: Is there any long–term benefit from coronary artery bypass surgery ? J Am Coll Cardiol 1988; 12: 881–882.        [ Links ]

484. Crossman AW, D'Agostino HJ, Geraci SA: Timing of coronary artery bypass graft surgery following acute myocardial infarction: a critical literature review. Clin Cardiol 2002; 25(9): 406–10.        [ Links ]

485. Locker C, Shapira I, Paz Y, et al: Emergency myocardial revascularization for acute myocardial infarction: survival benefits of avoiding cardiopulmonary bypass. Eur J Cardiothorac Surg 2000; 17(3): 234–8.        [ Links ]

486. Loubani M, Chin D, Leverment JN, Galinanes M: Mid–term results of combined transmyocardial laser revascularization and coronary artery bypass. Ann Thorac Surg 2003; 76(4): 1163–6.        [ Links ]

487. Mehlhorn U, Kroner A, de Vivie ER: 30 years clinical intra–aortic balloon pumping: facts and figures. Thorac Cardiovasc Surg 1999; 47(Suppl 2): 298–303.        [ Links ]

488. Hill AG, Groom RC, Burton NA, Lefrak EA: Cardiac assist devices. Int Anesthesiol Clin 1996; 34(2): 85–94.        [ Links ]

489. Baron DW, O'Rourke MF: Long–term results of arterial counterpulsation in acute severe cardiac failure complicating myocardial infarction. Br Heart J 1976; 38(3): 285–8.        [ Links ]

490. Klein W, Hödl R, Kraxner W: Diagnosis and Risk Stratification in Patients With Acute Coronary Syndromes According to ESC Guidelines. Thrombosis Research 2001; 103: S57–S61.        [ Links ]

491. Ward RP, Lang RM: Myocardial Contrast Echocardiography in Acute Coronary Syndromes. Curr Opin Cardiol 2002; 17: 455–63.        [ Links ]

492. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, et al: ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42(7): 1318–1333.        [ Links ]

493. Yang PC, Meyer CH, Terashima M, Kaji S, McConnell MV, Macovski A, Pauly JM, et al: Spiral magnetic resonance coronary angiography with rapid real–time localization. J Am Coll Cardiol 2003; 41: 1134–41.        [ Links ]

494. Neubauer S, Revel D, Roos A, Van Rossum A, Von Schulthess G, Sechtem U, Sieverding L, et al: The clinical role of magnetic resonance in cardiovascular disease Task Force of the European Society of Cardiology, in Collaboration with the Association of European Paediatric Cardiologists. European Heart Journal 1998; 19: 19–39.        [ Links ]

495. Kwong RY, Schussheim AE, Rekhraj S, Aletras AH, Geller N, Davis J, Christian TF, et al: Detecting Acute Coronary Syndrome in the Emergency Department With Cardiac Magnetic Resonance Imaging. Circulation 2003; 107: 531–537.        [ Links ]

496. Schroeder S, Kopp AF, Baumbach A, Meisner C, Kuettner A, Georg C, Ohnesorge B, et al: Noninvasive Detection and Evaluation of Atherosclerotic Coronary Plaques With Multislice Computed Tomography. J Am Coll Cardiol 2001; 37: 1430–5.        [ Links ]

497. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Las key WK, Pennell DJ, et al: Standarized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the Heart. A Statement for Healthcare Professionals From the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539–42.        [ Links ]

497a. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davidson TW, et al: ACC/AHA Guidelines for the Clinical Application of Echocardiography. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Committee on Clinical Application of Echocardiography). Developed in Collaboration With the American Society of Echocardiography. Circulation 1997; 95: 1686–1744.        [ Links ]

497b. Evangelista–Masip A, Alonso–Gómez AM, Duran RM, Moreno–Yagüela M, Oliver–Ruiz JM, Rodríguez–Padial L, Tobaruela A: Guías de práctica clínica de la Sociedad Española de Cardiología en Ecocardiografía. Rev Esp Cardiol 2000; 53: 663–683.        [ Links ]

497c. Roxy S, Antoinette K, Petros N: Stress echocardiography for assessing myocardial ischaemia and viable myocardium. Heart 1997; 78(2S) Suppl 1: 12–18.        [ Links ]

498. O'Conor GT, Buring JE, Yusuf S: An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989; 80: 234–244        [ Links ]

499. Stable A, Mattsson E, Ryden L: Improved physical fitness and quality of life following training of elderly patients after acute coronary events. Eur Heart J 1999; 20: 1475–84.        [ Links ]

500. Denottet J, Brutsaert D: Personality, disease severity and the risk of long–term cardiac events in patients with a decreased ejection fraction after myocardial infarction. Circulation 1998; 97: 167–173.        [ Links ]

501. De Longerril M, Salen P, Martin JL: Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779–85.        [ Links ]

502. Burr ML, Fehily AM, Gilbert JF, Rogers S: Effects of changes in fat, fish and fiber intakes on death and myocardial reinfarctions: diet and reinfarction trial. Lancet 1989; 2: 757–761.        [ Links ]

503. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO–HOPE substudy. Lancet 2000; 355: 253–9        [ Links ]

504. Dorn J, Naughton J, Imamura D: Results of a multicenter randomized clinical trial of exercise and long–term survival in myocardial infarction patients: The National Exercise and Heart Disease Project (NEHDP). Circulation 1999; 100: 1764–69.        [ Links ]

505. Working Group on Rehabilitation of the European Society of Cardiology: Long–term comprehensive care of cardiac patients. Recommendations by the working group. Eur Heart J 1992; 13(suppl C): 1–45.        [ Links ]

506. Shaper AG, Pocock SJ, Walker M, Philips AN: Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health 1985; 39: 197–209.        [ Links ]

507. Aberg A, Bergstrand R, Johansson S: Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J 1983; 49: 416–22.        [ Links ]

508. Wilhemsson C: Coronary heart disease: epidemiology of smoking and intervention studies of smoking. Am Heart J 1988; 115: 242–249.        [ Links ]

509. Daly LE, Mulcahy R, Graham IM, Hickey N: Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983; 287: 324–26.        [ Links ]

510. Taylor CB, Houston–Miller N, Killen JD: Smoking cessation after acute myocardial infarction: effects of a nurse–managed intervention. Ann Internal Med 1990; 113: 118–23.        [ Links ]

511. Silagy C, Mant D, Fowler G, Lancaster T: Nicotine replacement therapy for smoking cessation (Cochrane Review) 1997 Oxford Update Software.        [ Links ]

512. AntithromboticTrialists'Collaboration: Collaborative meta–analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 103–5.        [ Links ]

513. Julian DG, Chamberlain DA, Pocock SJ: A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomized clinical trial. BMJ 1996; 313: 1429–31.        [ Links ]

513a. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST–segment elevation. N Engl J Med 2001; 345: 494–502.        [ Links ]

514. Smith P, Amensen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147–52.        [ Links ]

515. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Efect of long–term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994; 343:499–503.        [ Links ]

516. Fuster V, Lars ER: Management of Patients with atrial fibrillation. American college of cardiology, American heart association and European society of cardiology. 2002: 35–7.        [ Links ]

517. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: SPAF II Study. Lancet 1994; 343: 687–691.        [ Links ]

518. Coumadin Aspirin Reinfarction Study (CARS) investigators: Randomized double–blind trial of low–dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study. Lancet 1997; 350: 389–96.        [ Links ]

518a. Anand SS, Yusuf S: Oral anticoagulant therapy in patients with coronary artery disease: a meta–analysis. JAMA 1999; 282: 2058–67.        [ Links ]

519. Fiore LE, Brophy MT, et al, for the Combination Hemotherapy and Mortality Prevention Study Group Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: Primary results of the CHAMP study Circulation 2002; 105: 557–63        [ Links ]

520. Van Es RF, Jonker JJ, Verheugt FW et al: Antithrombotics in the Secondary Prevention of Events in Coronary Trombosis–2 (ASPECT–2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT–2 study): a randomized controlled trial. Lancet 2002; 360: 109–13        [ Links ]

521. Hurien M, Abdeinoor M, Smith P, et al: Warfarin, aspirin, or both after myocardial infarction. N Engl Med 2002; 347: 969–74.        [ Links ]

522. Perdersen TR: Six–year follow–up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med 1985; 313: 1059–8.        [ Links ]

522a. Olsson G, Oden A, Johansson L, et al: Prognosis after withdraw I of chronic postinfarction metoprotol treatment: a 2 to 7 year follow–up. Eir Heart J 1988; 9: 365–72.        [ Links ]

522b. The MERIT–HF investigators: Effect of metoprotol CR/XL in chronic heart failure: Metoprotol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT–HF). Lancet 1999; 353: 2001–7.        [ Links ]

522c. The CIBIS–II investigators: The Cardiac Insufficiency Bisoprostol Study II. (CIBIS–II): a randomized trial. Lancet 1999; 353: 9–13.        [ Links ]

523. The Beta–Blocker Pooling Project Research Group: The Beta–Blocker pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8–16.        [ Links ]

524. Held PH, Yusuf S, Furberg CD: Calcium channel Mockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187–1192.        [ Links ]

525. The Danish Study group on Verapamil in Myocardial infarction: Effect of verapamil on mortality and major events after myocardial infarction (the Danish Verapamil infarction Trial DAVIT II). Am J Cardiol 1990; 66: 779–85.        [ Links ]

526. The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385–92.        [ Links ]

527. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Eng J Med 1992; 327: 669–77.        [ Links ]

528. The Acute infarction Ramipril Efficacy (AIRE) Study investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8.        [ Links ]

529. Kober L, Torp–Pedersen C, Carlsen JE, et al: A clinical trial of the angiotensin–converting–enzyme inhibidor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9–12.        [ Links ]

530. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO–HOPE substudy. Lancet 2000; 355: 253–9.        [ Links ]

531. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. NEJM 1999; 341:709–17.        [ Links ]

532. Rodríguez JA, Godoy I, Castro P, et al: Ramipril vs espironolactona en el remodelamiento ventricular izquierdo post–infarto: randomizado y doble ciego. Rev Med Chile 1997; 125: 643–52.        [ Links ]

533. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD: Effects of adding spironolactone to an angiotensin–converting enzyme inhibition in chronic congestive heart failure secondary to coronary artery disease. AM J Cardiol 1995; 76: 1259–65.        [ Links ]

534. Pitt B, Remme W, Zannad F, et al: Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial infarction. N Engl J Med 348; 14: 1309–1321.        [ Links ]

535. The Scandinavian Simvastatin Survival Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet 1994; 344: 1383–9.        [ Links ]

536. Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001–9.        [ Links ]

537. The Long–Term Intervention with Pravastatin in ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57.        [ Links ]

538. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo–controlled trial. Lancet 2002; 360: 7–22.        [ Links ]

538a. Dupuis J, Tardif JC, Cernacek P, Therroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE [reduction of Cholesterol in ischemia and Function of the Endoteliun] trial. .Circulation 1999; 99: 3227–3233        [ Links ]

539. Strenestrand U, Wallentin L: Early statin treatment following acute myocardial infarction and 1–year survival. JAMA 2001; 285: 430–6        [ Links ]

540. Cannon C, Braunwald E, McCabe C, Rader D: For the pravastatin or athorvastatin evaluation and infection therapy–thrombolysis in myocardial infarction 22 Investigators. NEJM 2004; 350(15): 1495–1504.        [ Links ]

541. Blazing M: Early intensive vs a delayed conservative simvastatine strategy in patients with acute coronary syndrome. On behalf AtoZ Trial Investigators. Oral presentation ESC Meeting Aug 25, 2004.        [ Links ]

542. Nissen S, Tuzcu E, Schoenhagen P, Braun G, Ganz P, Vogel R, Crowe T, Howard G: For the REVERSAL Investigators. JAMA 2004; 291(9): 1071–1081.        [ Links ]

543. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high–density lipoprotein cholesterol. Veterans Affairs High–Density Lipoprotein Cholesterol intervention Trial Study Group. N Engl J Med 1999; 341: 410–8.        [ Links ]

544. The BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerices in patients with coronary artery disease. The Bezafribrate infarction Prevention (BIP) Study. Circulation 2000; 102: 21–7.        [ Links ] ]]> 1 Secretaría de Salud 2001 2 1979 59 59 607-609 3 1999 20 20 1459-1464 4 2000 36 36 959-969 5 1978 73 73 743-749 6 1983 68^sI 68^sI I 1-25-36 7 1998 78 78 1345-1373 8 1998 31 31 326-330 9 2001 38 38 987-990 10 1999 45 45 18-20 11 1999 284 284 151-158 12 1999 59^s230 59^s230 230 83-89 12a 2003 348 348 933-940 12b 1992 2 471-481 13 14 1997 15 1990 65 65 687-691 16 1991 84^sI 84^sI I 1-109-121 17 1972 34 34 67-80 18 MONICA Project 1999 353 353 1547-57 19 1991 18 18 698-706 20 2002 15 15 1190-1201 21 Grupo Cooperativo RENASICA 2002 ^s72 ^s72 72 S45-S64 22 1912 59 59 2015 23 1989 303 303 897-902 24 1999 25 1995 92 92 1355-1374 26 1985 53 53 363-373 27 1989 II II 941-944 28 1991 68^sB 68^sB B 28B-35B 29 1995 91 91 2844-2850 30 1990 2 2 199-210 31 1992 326 326 242-250 32 1999 33 1995 332 332 1553-1559 34 1989 14 14 850-859 35 2000 101 101 570-580 36 2003 24 24 28-66 37 GREAT Group 1993 307 307 409-413 38 1995 16 16 325-332 39 1985 5 5 193-197 40 1995 91 91 1659-1668 41 2000 102 102 2031-2037 42 2001 358 358 1571-1575 43 2005 45 45 1594-1599 44 2000 21 21 1406-1432 45 2005 75 75 S18-S30 46 2005 111 111 3481-3488 46a 2004 25 25 1187-1196 47 GRACE Investigators 2002 359 359 373-377 48 1995 25 25 521-547 49 2000 21 21 1047-1074 50 2000 105 105 162-167 50a 1975 52 52 360-368 50b 1976 53 53 198-200 50c 1970 79 79 620-629 51 1974 54 54 563-575 51a 2001 6 1114-1251 52 1976 79 79 620-629 52a 53 1999 53a ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group 1995 345 345 669-85 54 1988 1 1 1088-1092 54a 1972 106 106 721-728 55 Fourth International Study of infarct Survival (ISSIS-4) Collaborative Group 1995 345 345 669-685 55a 1970 41 41 1025-1030 56 Grupo Italiano per lo studio della streptochinasi nell infarto miocardio (GISSI) GISSI3 1994 343 343 1115-1122 56a 1971 12 12 719-723 57 1980 45 45 535-540 57a 1974 290 290 761-765 58 Antiplatelet Trialist Collaboration 1994 308 308 81-106 58a 1968 35 35 115-122 59 Second International Study of infarct Survival (ISSIS 2) Collaborative Group 1988 II II 349-360 60 ISSIS study Group 1987 60 60 6A-12A 61 First International Study of Infarct Survival (ISSIS 1) 1986 ii57-56 62 CAPRICORN Investigators 2001 357 357 1385-90 63 ACE inhibitor Myocardial Infarction Collaborative Group 1998 97 97 2202-2212 64 1997 337 337 447-52 65 ISSIS 3 1992 339 339 753-70 66 2002 102 102 11-826 67 ACS investigators 2001 357 357 1915-24 68 2001 285 285 1711-1718 69 2001 37 37 A334 70 1998 98 98 2227-2234 70b 2004 71 2003 73 73 46-58 72 2002 23 23 1146-1148 73 2000 36 36 1497-1499 74 The Cardiac Catheterization and Antithrombotic Therapy and Tools in Hospital (CATH) Clinical Consensus 2003 233-268 75 2003 92 92 824-26 76 1995 16 16 1024-1026 77 1980 330 330 897-902 78 1989 79 79 441-444 79 1994 1 1 27-34 80 Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI) 1986 1 1 397-402 81 Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI) 1987 2 2 871-874 82 ISAM Study Group 1986 314 314 1465-1469 83 ISAM Study Group 1987 76^s2 76^s2 2 1144-1151 84 ISAM Study Group 1987 9 9 197-203 85 1988 2 2 525-530 86 AIMS Trial Study Group 1988 1 1 545-549 87 1988 77 77 345-352 88 1989 14 14 1159-65 89 The TIMI Study Group 1989 320 320 618-627 90 1989 64 64 448-453 91 1989 14 14 1566-1569 92 Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI-2) 1990 336 336 65-71 93 The International Study Group 1990 336 336 673-682 94 The GUSTO investigators 1993 329 329 673-682 95 EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group 1993 342 342 767-772 96 LATE Study Group 1993 342 342 759-766 97 Fibrinolytic Therapy Trialist's (FTT) Collaborative Groups 1994 343 343 311-322 98 1994 24 24 1602-1610 99 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators 1997 337 337 1118-1123 100 1997 95 95 351-356 101 Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators 1999 354 354 716-722 102 The in Time-II Investigators 2000 21 21 2005-2013 103 Assessment of the safey and efficacy of a new thrombolytic regimen (ASSENT-3) Investigators 2001 358 358 605-613 104 The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial investigators 2001 358 358 1855-1863 105 2002 23 23 1282-1290 106 1999 617 617 991-995 107 1996 348 348 771-775 108 1985 6 6 556-585 109 1999 69 69 478-487 110 Thrombolysis in Acute Myocardial Infarction Group (TAMI-6) 1992 85 85 2090-2099 111 1996 66 66 484-488 112 The European Myocardial Infarction Project Group 1993 329 329 382-389 113 Myocardial Infarction Triage and Intervention Project Group 1993 270 270 1211-1216 114 GREAT Group 1992 305 305 548-553 115 1995 16^s123 16^s123 123 116 1996 93 93 45-53 117 2002 40 40 71-77 118 2003 327^s22-26 327^s22-26 22-26 119 2003 327 327 27-28 120 2002 360 360 825-829 121 1993 328 328 726-728 122 1995 26 26 668-674 123 2001 85 85 104-112 124 1995 65 65 323-329 125 1992 1 1 275A 126 1990 16 16 779-783 127 1990 64 64 177-181 128 1993 71 71 524-528 129 2002 31 31 113-121 130 2003 73 73 S2-17 131 2000 132 132 556-565 132 1999 69 69 163-175 133 1999 69 69 570-579 134 GUSTO V Investigators 2001 357 357 1905-1914 135 1987 59 59 1-5 136 1993 61 61 85 137 1990 16 16 533-540 138 1990 112 112 17-21 139 1993 61 61 58 140 1999 34 34 1395-1402 141 1999 99 99 2720-32 142 1997 32 32 381-9 143 1998 31^sA 31^sA A 191A 144 1996 94^s1 94^s1 1 1-553 145 2000 101 101 2788-2794 146 2000 36 36 1489-1496 147 2002 39 39 377 148 1990 65 65 1292-1296 149 1989 63 63 102-104 150 1990 65 65 924-926 151 1989 14 14 1609-1615 152 1986 74 74 1379-1389 153 1996 28 28 1661-1669 154 TIMI-IIIB Investigators 1994 89 89 1545-1556 155 1996 66 66 254-264 156 1995 26 26 1643-1650 157 1996 27 27 1321-1332 158 2001 2 47-70 159 1981 9 9 424-425 160 1988 78 78 II-127A 161 1991 73L 73L 953-957 162 1994 73 73 953-958 163 2001 357 357 1583-1588 164 2003 349 349 2128-35 165 1996 334 334 481-484 166 1968 186-205 167 1988 12 12 1156-1166 168 1993 63 63 463-478 169 1993 63 63 563-565 170 2002 72 72 311-349 171 2001 38 38 1283-1294 172 2003 348 348 933-940 173 2003 56 56 16-19 174 2001 119 175 GRACE Investigators 2002 359 359 373-377 176 1996 110 110 107S 177 1989 14 14 1566-1569 178 1993 5 8 8 15-24 179 1995 ^s25 ^s25 25 18S-22S 180 1994 331 331 1130-1135 181 1993 88^sI 88^sI I 1-507 182 1997 30 30 1611-1617 183 1997 67 67 126-131 184 2003 17 17 1-25 185 2001 2 186 1990 16 16 223-231 187 2000 140 140 S154-S160 188 2001 2 169-179 189 2001 71 71 S3-106 190 Collaborative Group of the Primary Prevention Project (PPP) 2001 387 387 89-95 191 CAPRIE investigators 2000 140 140 67-73 192 STAMI group 2001 37 37 1259-1265 193 1986 56 56 147-150 194 1998 9 9 251-255 195 CAPRIE Steering Committee 1996 348 348 1329-1339 196 1994 93 93 615-632 197 1997 8 8 385-390 198 1998 80 80 512-518 199 2000 101 101 2823-2828 200 CLASSICS Investigators 2000 102 102 624-629 200a 2005 352 12 12 1179-1189 201 1996 313 313 652-659 202 1995 91 91 1923-1928 203 1989 79 79 281-286 204 1999 33 33 627-633 205 1989 86 86 7585-7589 206 1977 74 74 4033-4036 207 1990 323 323 1433-1437 208 1992 67 67 122-128 209 The GUSTO Angiographic Investigators 1993 22 22 1615-1622 210 2001 141 141 742-750 211 1996 93 93 870-878 212 1991 333-348 213 2003 289 289 331-342 214 1985 5 5 319-332 215 1996 77 77 1145-1148 216 1996 26 26 247-257 217 European Study of Prevention of Infarct with Molsidomine (ESPRIM) Group 1994 344 344 91- 97 218 2002 347 347 5-12 219 2000 343 343 915-922 220 2002 106 106 804-808 221 1993 22 22 695-706 222 The Norwegian Multicenter Study Group 1981 304 304 801-807 223 1981 2 2 823-827 224 Beta-Blocker Heart Attack Trial Research Group 1982 247 247 1707-1714 225 1993 11^s4 11^s4 4 S61-73 226 1991 83 83 422-37 227 1993 2 2 407-16 228 1998 32 32 634-640 229 1999 318 318 1730-1737 230 Chinese Cardiac Study Collaborative Group 1995 345 345 686-687 231 1992 327 327 678-84 232 1995 75 75 1173-5 233 1993 72 72 145G-155G 234 1989 299 299 1122-1187 235 1991 67 67 1295-1297 236 1988 260 260 1910-1916 237 1991 303 303 1499-503 238 1992 339 339 1553-1558 239 2002 Berlin 240 GUSTO Angiographic Investigators 1993 329 329 1615-22 241 1998 97 97 1150-6 242 1988 109 109 970-80 243 2002 166 166 51-61 244 2000 342 342 1573-80 245 1979 104 104 1401-1405 246 2004 147 147 133-199 247 2003 145 145 862-867 248 2003 361 361 13-20 249 1999 341 341 1413-1419 250 1999 33 33 640-646 251 2003 107 107 2538-2542 252 1999 341 341 1949-56 253 2002 346 346 957-66 254 1991 115 115 173-7 255 1991 67 67 7-12 256 1999 99 99 2720-2732 257 GUSTO V Investigators 2001 357 357 1905-1914 258 2001 358 358 605-613 259 SASTRE Investigators 2004 93 93 280-287 260 2004 291 291 947-954 261 2004 262 2004 147 147 E16 263 ADMIRAL Investigators 2001 344 344 1895-1903 264 2004 25 25 837-846 265 2003 107 107 1497-1501 266 2004 25 25 2125-2133 267 2004 292 292 362-366 268 1991 115 115 173-177 269 1999 82 82 426-431 270 2000 21 21 823-831 271 2003 24 24 94-104 272 2002 39 39 1713-1719 273 2003 349 349 733-742 274 1997 78 78 333-336 275 2003 108 108 1084-1088 276 2001 142 142 105-111 277 2002 360 360 825-829 278 PCAT collaboration 4 h) presentation treated by primary and coronary angioplasty or thrombolytic therapy por acute myocardial infarction]]> 2002 23 23 550-557 279 1995 41 41 1228-33 280 1995 25 25 574-81 281 1996 27^sA 27^sA A A-222 282 1995 76 76 1108-11 283 1998 90 90 48-51 284 2000 132 132 556-565 285 2001 358 358 605-613 286 1998 31 31 1246-51 287 1998 1 1 197-203 288 1998 32 32 629-33 289 The TIMI Study Group 1989 320 320 618-27 290 1994 90 90 2280-4 291 1992 8 8 357-62 292 1991 83 83 1543-56 293 1992 19 19 681-6 294 1994 74 74 172-4 295 1997 80 80 21-6 296 1998 31 31 1511-7 297 1998 82 82 554-8 298 1996 77 77 1045-51 299 2000 139 139 1046-53 300 2003 42 42 7-16 301 1996 77 77 685-9 302 1999 47 47 1-5 303 1996 77 77 1045-51 304 2001 9 9 31-35 305 1991 121 121 895-901 306 1991 122 122 385-9 307 1994 90 90 792-9 308 1997 29 29 1459-67 309 1995 76 76 73-5 310 2003 16 16 209-16 311 1987 317 317 581-8 312 1988 1 1 197-203 313 TIMI Research Group 1988 260 260 2849-58 314 2003 42 42 634-41 315 TIMI Study Group 1989 320 320 618-27 316 1992 85 85 533-42 317 SWIFT Trial Study Group 1991 302 302 555-60 318 1997 96 96 748-755 319 1994 89 89 61-7 320 2002 106 106 1051-4 321 Fibrinolytic Therapy Trialists Collaborative Group 1994 343 343 311-22 322 1989 79 79 441-4 323 1990 88 88 9-15N 324 2001 142 142 411-21 325 1999 83 83 482-487 326 1992 20 20 307-13 327 1995 11 11 378 84 328 1995 92 92 1101-9 329 1992 86 86 1400-6 330 2002 40 40 869-76 331 2003 108 108 1324-8 332 1987 75 75 988-995 333 1983 4 4 461-472 334 1988 9 9 447-453 335 1987 59 59 241-244 336 1994 42-44 337 1987 30 30 73-110 338 1978 41 41 1127-1132 339 1988 260 260 2088-2093 340 2002 72^s2 72^s2 2 45-64 341 1998 31 31 94-102 342 1998 338 338 1488-1497 343 1996 344 1995 1 1 10 345 1992 3 3 713-720 346 1994 90 90 1537-1541 347 1989 117 117 86-92 348 1990 66 66 1418-1421 349 1995 333 350 1994 17 17 471-478 351 1981 101 101 750-753 352 1990 65 65 709-730 353 Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardico, GISSI-2 1990 336 336 65-71 354 The International Study Group 1990 336 336 71-75 355 1997 80 80 859-64 356 2000 23 23 751-758 357 1994 15 15 761-768 358 2002 39 39 1450-5 359 1981 64 64 1005-1011 360 1995 35 35 18-28 361 1986 7 7 289-298 362 1987 8 8 1201-1209 363 2001 37 37 37-43 364 1993 328 328 981-988 365 1967 20 20 457-64 366 1976 295 295 1.356-1.362 367 1995 91 91 873-81 368 1991 325 325 1117-22 369 1996 28 28 1328-1428 370 2000 36 36 1110-6 371 1970 26 26 556-64 372 1989 14 14 40-6 373 1993 94 94 265-73 374 1996 27 27 1321-1326 375 1975 36 36 185-96 376 1977 39 39 588-94 377 1981 245 245 144-6 378 1973 32 32 79-84 379 1977 19 19 327-40 380 1983 67 67 620-6 381 1953 15 15 330-43 382 1997 5 5 207-13 383 1998 384 AIMS Trial Study Group 1988 1 1 545-9 385 2000 36 36 1123-9 386 1994 105 105 997-1002 387 1998 31^sA 31^sA A 135A 388 1996 78 78 35-40 389 1973 288 288 979-984 390 1978 58 58 204-210 391 1979 42 42 579-582 392 1980 61 61 1105-1112 393 1981 102 102 1049-1060 394 1978 58^sI 58^sI I I-69-I-72 395 1980 29 29 153-155 396 1980 62^sI 62^sI I 1123-9 397 1994 90 90 792-799 398 1990 19 19 160-164 399 1970 25 25 546-551 400 1994 17 17 602-636 401 1991 17 17 599-603 402 1992 20 20 1482-1489 403 1997 29 29 1459-67 404 1997 45 45 55-9 405 2003 41 41 1940-5 406 1999 341 341 625-34 407 1995 25 25 1333-40 408 2003 41 41 1273-9 409 1987 113 113 257-260 410 1984 108 108 5-13 411 1990 812-23 412 Multiple Risk Factor Intervention Trial Research Group 1993 16 16 434-444 413 1995 2 429-48 414. 1985 110 110 1100-1107 415 1992 20 20 736-744 416 GUSTO-I Investigators 1997 30 30 171-179 417 GISSI-2 Investigators 1993 22 22 1788-1794 418 SAVE Investigators 1991 266 266 528-532 419 Fragmin during Instability in Coronary Artery Disease (FRISC) study group 1996 347 347 561-568 420 FRIC Investigators 1997 96 96 61-68 421 1999 33^sA 33^sA A 352A 422 EPISTENT Investigators 1998 352 352 87-92 423 EPISTENT Investigators 1999 100 100 2477-2484 424 1995 12 12 426-428 425 1995 123 123 358-367 426 1997 96 96 4239-4245 427 Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators 1995 332 332 80-85 428 DIGAMI Study Group 1996 17 17 1337-1344 429 1999 99 99 2626-2632 430 1993 329 329 1442-1448 431 75 years with that in younger patients]]> 1995 75 75 573-576 432 1999 14 14 427-435 433 2000 23 23 831-836 434 2000 36 36 1194-1201 435 2002 40 40 394-402 436 1993 328 328 673-679 437 1993 328 328 680-684 438 1993 328 328 685-691 439 2000 36 36 723-730 440 1986 8 8 252-256 441 1985 313 313 1105-10 442 Diamond Study Group 1998 98 98 1-93 443 1998 351 351 478-484 444 1996 335 335 1933-1940 445 1999 341 341 1882-1890 446 1997 337 337 1569-1575 447 2002 346 346 877-883 448 Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators 2004 350 350 2140-2150 449 2004 350 350 2151-2158 450 DINAMIT Investigators 2000 140 5 5 735-739 451 2004 452 1999 118 1 1 50-6 453 2002 74 74 102-8 454 1995 60 1 1 19-26 455 1984 88 6 6 914-21 456 85 11 11 1292-6 457 2002 25 9 9 406-10 458 1996 94^s9 94^s9 9 1181-6 459 1999 99 99 2829-2848 460 1986 73 73 233-239 461 2000 53 2 2 241-66 462 2003 76 76 771-7 463 1999 3-71 464 2000 102 102 1193-1209 465 1999 34 4 4 1262-347 466 2000 69 1 1 51-5 467 1994 9 2 2 97-102 468 2003 14 6 6 463-70 469 2002 13 6 6 337-44 470 1995 16 11 11 1736-8 471 1991 52 3 3 474-8 472 1992 104 4 4 961-5 473 2003 4 3 3 131-5 474 2002 53 6 6 721-6 475 1998 51^s3 51^s3 3 71-9 476 2002 87 6 6 569 477 1995 70 9 9 880-4 478 2003 24 9 9 828-37 479 2002 25 9 9 406-10 480 2003 125 1 1 115-9 481 2002 90 1 1 35-8 482 1995 59 5 5 1169-76 483 1988 12 12 881-882 484 2002 25 9 9 406-10 485 2000 17 3 3 234-8 486 2003 76 4 4 1163-6 487 1999 47^s2 47^s2 2 298-303 488 1996 34 2 2 85-94 489 1976 38 3 3 285-8 490 2001 103 103 S57-S61 491 2002 17 17 455-63 492 2003 42 7 7 1318-1333 493 2003 41 41 1134-41 494 1998 19 19 19-39 495 2003 107 107 531-537 496 2001 37 37 1430-5 497 2002 105 105 539-42 497a 1997 497b 2000 53 53 663-683 497c 1997 78 2S^s1 2S^s1 1 12-18 498 1989 80 80 234-244 499 1999 20 20 1475-84 500. 1998 97 97 167-173 501 1999 99 99 779-85 502 1989 2 2 757-761 503 Heart Outcomes Prevention Evaluation Study Investigators 2000 355 355 253-9 504 1999 100 100 1764-69 505 Working Group on Rehabilitation of the European Society of Cardiology 1992 13^sC 13^sC C 1-45 506 1985 39 39 197-209 507 1983 49 49 416-22 508 1988 115 115 242-249 509 1983 287 287 324-26 510 1990 113 113 118-23 511 1997 512 AntithromboticTrialists'Collaboration 2002 324 324 103-5 513 1996 313 313 1429-31 513a The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial investigators 2001 345 345 494-502 514 1990 323 323 147-52 515 Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group 1994 343 343 499-503 516 2002 35-7 517 Stroke Prevention in Atrial Fibrillation Investigators 1994 343 343 687-691 518 Coumadin Aspirin Reinfarction Study (CARS) investigators 1997 350 350 389-96 518a 1999 282 282 2058-67 519 2002 105 105 557-63 520 2002 360 360 109-13 521 2002 347 347 969-74 522 1985 313 313 1059-8 522a 1988 9 9 365-72 522b The MERIT-HF investigators 1999 353 353 2001-7 522c The CIBIS-II investigators 1999 353 353 9-13 523 The Beta-Blocker Pooling Project Research Group 1988 9 9 8-16 524 1989 299 299 1187-1192 525 1990 66 66 779-85 526 The Multicenter Diltiazem Postinfarction Trial Research Group 1988 319 319 385-92 527 1992 327 327 669-77 528 The Acute infarction Ramipril Efficacy (AIRE) Study investigators 1993 342 342 821-8 529 1999 354 354 9-12 530 Heart Outcomes Prevention Evaluation Study Investigators 2000 355 355 253-9 531 1999 341 341 709-17 532 1997 125 125 643-52 533 1995 76 76 1259-65 534 348 14 14 1309-1321 535 The Scandinavian Simvastatin Survival Group 1994 344 344 1383-9 536 1996 335 335 1001-9 537 The Long-Term Intervention with Pravastatin in ischaemic Disease (LIPID) Study Group 1998 339 339 1349-57 538 Heart Protection Study Collaborative Group 2002 360 360 7-22 538a 1999 99 99 3227-3233 539 2001 285 285 430-6 540 2004 350 15 15 1495-1504 541 2004 542 2004 291 9 9 1071-1081 543 1999 341 341 410-8 544 The BIP Study Group 2000 102 102 21-7